<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Dev Biol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Dev Biol</journal-id><journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id><journal-title-group><journal-title>Frontiers in Cell and Developmental Biology</journal-title></journal-title-group><issn pub-type="epub">2296-634X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38188015</article-id><article-id pub-id-type="pmc">PMC10771851</article-id>
<article-id pub-id-type="publisher-id">1308082</article-id><article-id pub-id-type="doi">10.3389/fcell.2023.1308082</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cell and Developmental Biology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Claudins in genitourinary tract neoplasms: mechanisms, prognosis, and therapeutic prospects</article-title><alt-title alt-title-type="left-running-head">Arabi et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fcell.2023.1308082" ext-link-type="uri">10.3389/fcell.2023.1308082</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Arabi</surname><given-names>Tarek Ziad</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1889585/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Ashraf</surname><given-names>Nader</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2155558/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Sabbah</surname><given-names>Belal Nedal</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1902066/overview"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ouban</surname><given-names>Abderrahman</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/1544121/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>College of Medicine</institution>, <institution>Alfaisal University</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Pathology</institution>, <institution>College of Medicine</institution>, <institution>Alfaisal University</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/5026/overview" ext-link-type="uri">Igor Jakovcevski</ext-link>, Witten/Herdecke University, Germany</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/2194979/overview" ext-link-type="uri">Kranthi Kiran Kishore Tanagala</ext-link>, Columbia University, United States</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/754098/overview" ext-link-type="uri">Panagiota S. Filippou</ext-link>, Teesside University, United Kingdom</p></fn><corresp id="c001">*Correspondence: Abderrahman Ouban, <email>aouban@alfaisal.edu</email>
</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>11</volume><elocation-id>1308082</elocation-id><history><date date-type="received"><day>05</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>11</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2023 Arabi, Ashraf, Sabbah and Ouban.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Arabi, Ashraf, Sabbah and Ouban</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Genitourinary (GU) cancers are among the most prevalent neoplasms in the world, with bladder cancers constituting 3% of global cancer diagnoses. However, several pathogenetic mechanisms remain controversial and unclear. Claudins, for example, have been shown to play a significant role in several cancers of the human body. Their role in GU cancers has not been extensively studied. Aberrant expression of claudins &#x02212;1, &#x02212;2, &#x02212;3, &#x02212;4, &#x02212;7, and &#x02212;11 has been expressed in urothelial cell carcinomas. In prostate cancers, altered levels of claudins &#x02212;1, &#x02212;2, &#x02212;3, &#x02212;4, and &#x02212;5 have been reported. Furthermore, the levels of claudins &#x02212;1, &#x02212;2, &#x02212;3, &#x02212;4, &#x02212;6, &#x02212;7, &#x02212;8, and &#x02212;10 have been studied in renal cell carcinomas. Specifically, claudins &#x02212;7 and &#x02212;8 have proven especially useful in differentiating between chromophobe renal cell carcinomas and oncocytomas. Several of these claudins also correlate with clinicopathologic parameters and prognosis in GU cancers. Although mechanisms underpinning aberrant expression of claudins in GU cancers are unclear, epigenetic changes, tumor necrosis factor-&#x00251;, and the p63 protein have been implicated. Claudins also provide therapeutic value through tailored immunotherapy via molecular subtyping and providing therapeutic targets, which have shown positive outcomes in preclinical studies. In this review, we aim to summarize the literature describing aberrant expression of claudins in urothelial, prostatic, and renal cell carcinomas. Then, we describe the mechanisms underlying these changes and the therapeutic value of claudins. Understanding the scope of claudins in GU cancers paves the way for several diagnostic, prognostic, and therapeutic innovations.</p></abstract><kwd-group><kwd>claudins</kwd><kwd>carcinoma</kwd><kwd>urothelial cell</kwd><kwd>prostate</kwd><kwd>renal cell carcinoma</kwd><kwd>treatment</kwd><kwd>prognosis</kwd><kwd>diagnosis</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cell Adhesion and Migration</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>The barrier function of the epithelium is primarily maintained by tight junction proteins composed of zona-occludins, desmosomes, and claudins, among others (<xref rid="B2" ref-type="bibr">Arabi et al., 2023</xref>). The claudin family consists of 27 transmembrane proteins (<xref rid="B71" ref-type="bibr">Tsukita et al., 2019</xref>). Contrary to other tight junction proteins, some claudins function as paracellular channels and allow for the selective passage of water, anions, and cations (<xref rid="B23" ref-type="bibr">G&#x000fc;nzel and Fromm, 2012</xref>). Besides their channel and barrier roles, claudins have several biologic effects (<xref rid="F1" ref-type="fig">Figure 1</xref>). Claudins also play a role in cell migration through their effects on matrix metalloproteinases (MMP) (<xref rid="B73" ref-type="bibr">Venugopal et al., 2019</xref>). Furthermore, claudins, specifically claudin-2, also control the life cycle of cells and interact with several transcription factors, such as Sp1 and Zonula occludens 1-associated nucleic acid-binding protein (<xref rid="B73" ref-type="bibr">Venugopal et al., 2019</xref>). Claudins modulate several signaling pathways as well, including MEK/ERK/1/2 and PI-3K/Bcl-2 pathways (<xref rid="B1" ref-type="bibr">Ahmad et al., 2014</xref>; <xref rid="B73" ref-type="bibr">Venugopal et al., 2019</xref>). The broad spectrum of claudin functions is further solidified by claudin-knockout models, which lead to atopic dermatitis, renal hypoxia, seizures, and multiple sclerosis (<xref rid="B71" ref-type="bibr">Tsukita et al., 2019</xref>).</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>The physiologic functions of the claudin family of proteins in the human body. Besides their functions as barriers and channels, claudins also regulate cell proliferation through their interactions with transcription factors Sp1 and Zonula occludens 1-associated nucleic acid-binding protein (ZONAB), modulate cell migration through matrix metalloproteinases (MMPs), and serve as components of several signaling pathways such as MEK/ERK/1/2 and PI-3K/Bcl-2 pathways.</p></caption><graphic xlink:href="fcell-11-1308082-g001" position="float"/></fig><p>Emerging evidence has demonstrated that abnormal claudin expression can mediate tumorigenic processes in several cancers, including head and neck, gastrointestinal, breast, and lung neoplasms (<xref rid="B65" ref-type="bibr">Soini, 2011</xref>; <xref rid="B84" ref-type="bibr">Zhu et al., 2019</xref>; <xref rid="B76" ref-type="bibr">Yadav et al., 2022</xref>; <xref rid="B2" ref-type="bibr">Arabi et al., 2023</xref>). Additionally, aberrant expression of these proteins can be seen in preneoplastic conditions, highlighting their possible role for early detection and treatment of tumors (<xref rid="B51" ref-type="bibr">Ouban and Arabi, 2023</xref>).</p><p>Genitourinary (GU) cancers are among the most common cancers worldwide. For example, prostate cancers are the second most common solid tumors in men (<xref rid="B21" ref-type="bibr">Gandaglia et al., 2021</xref>). Bladder cancers constitute the 10th most common tumor worldwide, with 3% of all new cancer diagnoses (<xref rid="B10" ref-type="bibr">Bray et al., 2018</xref>). Unfortunately, due to higher rates of chemotherapy toxicity and comorbidities, elderly patients suffering from GU cancers often have poor cancer-related outcomes (<xref rid="B63" ref-type="bibr">Singhal et al., 2023</xref>). Hence, finding alternative treatment modalities may significantly increase the survival rates of this patient group.</p><p>Recent studies have shed some light on the role of claudins in GU cancers. For example, S&#x00103;ndulescu et al. demonstrated that claudin-4 expression is significantly increased in high-grade bladder urothelial carcinomas and those with invasion of the muscularis propria (<xref rid="B56" ref-type="bibr">S&#x00102;ndulescu et al., 2020</xref>). Similarly, elevated levels of claudin-3 have been reported in prostatic cancer patients compared to controls (<xref rid="B81" ref-type="bibr">Ye et al., 2019</xref>). Reports of aberrant claudin expression and its role in the development of GU cancers remain limited. Moreover, the mechanisms underlying these changes remain unclear. Therefore, we will gather the latest literature surrounding aberrant expression of claudins and their prognostic implications in GU cancers, including bladder, prostate, and renal cell carcinomas (RCC). Then, we discuss the mechanisms mediating changes in claudin expression and their value as therapeutic targets.</p></sec><sec id="s2"><title>2 Aberrant expression of claudins in urothelial carcinomas</title><p>Urothelial cells, previously known as transitional epithelial cells, line the lumen of the proximal urethra, bladder, ureters, and renal pelvis (<xref rid="B15" ref-type="bibr">Dalghi et al., 2020</xref>). The urothelium consists of several layers including the superficial umbrella cells, followed by the intermediate and basal layers, respectively (<xref rid="B15" ref-type="bibr">Dalghi et al., 2020</xref>). Urothelial carcinomas are seventh most common type of neoplasm and arises from the urothelium of the urethra, bladder, and ureters (<xref rid="B22" ref-type="bibr">Giudici et al., 2021</xref>). Bladder carcinomas are the most prevalent of urothelial carcinomas, constituting up to 95% of urothelial carcinomas (<xref rid="B22" ref-type="bibr">Giudici et al., 2021</xref>). Accordingly, the role of claudins in bladder carcinomas has been studied extensively. Claudin-1 can be detected at the membranes of high-grade urothelial carcinomas of the bladder (<xref rid="B57" ref-type="bibr">S&#x00103;ndulescu et al., 2022</xref>). However, a study by Elsen et al. found that both non-invasive bladder carcinoma and normal samples do not express claudin-1 (<xref rid="B16" ref-type="bibr">Elsen et al., 2015</xref>). Urothelial papillomas, papillary urothelial neoplasms of low malignant potential, and low-grade urothelial carcinomas of the bladder exhibit significantly less claudin-1 than inverted urothelial papillomas (<xref rid="B67" ref-type="bibr">Sz&#x000e9;kely et al., 2011</xref>). Increased claudin-1 expression is also associated with better recurrence-free survival in papillary urothelial neoplasms of low malignant potential (<xref rid="B67" ref-type="bibr">Sz&#x000e9;kely et al., 2011</xref>).</p><p>Claudin-2 can be seen as perimembranous cytoplasmic granules in the basal layers of nontumorous and tumorous urothelium (<xref rid="B69" ref-type="bibr">T&#x000f6;rzs&#x000f6;k et al., 2011</xref>). However, claudin-2 protein and messenger ribonucleic acid (mRNA) levels are increased in urothelial cell carcinomas compared to controls (<xref rid="B69" ref-type="bibr">T&#x000f6;rzs&#x000f6;k et al., 2011</xref>). Specifically, high-grade urothelial cell carcinomas express higher levels of claudin-2 mRNA compared to their low-grade counterpart (<xref rid="B69" ref-type="bibr">T&#x000f6;rzs&#x000f6;k et al., 2011</xref>). Claudin-3 is expressed in approximately 88% of urothelial carcinomas of the upper urinary tract on the upper epithelial layers (<xref rid="B45" ref-type="bibr">Nakanishi et al., 2008</xref>). Increased claudin-3 protein expression is associated with poor staging, grading, and pattern of tumor growth (<xref rid="B45" ref-type="bibr">Nakanishi et al., 2008</xref>). Although claudin-3 expression is correlated with overall survival rates in univariate analysis, multivariate analysis has failed to demonstrate a similar effect (<xref rid="B45" ref-type="bibr">Nakanishi et al., 2008</xref>).</p><p>A study by Chen et al. aimed to assess the alterations of tight junction proteins in bladder carcinoma cells compared to adjacent non-neoplastic tissue (<xref rid="B11" ref-type="bibr">Chen et al., 2020</xref>). The authors demonstrated elevated expression of claudin-4 in neoplastic tissue (<xref rid="B11" ref-type="bibr">Chen et al., 2020</xref>). However, claudin-4 levels are not associated muscle invasion, lymph node metastasis, or distant metastasis (<xref rid="B11" ref-type="bibr">Chen et al., 2020</xref>). Specifically, claudin-4 is overexpressed in low/medium-grade bladder carcinomas and becomes underexpressed in high-grade tumors (<xref rid="B9" ref-type="bibr">Boireau et al., 2007</xref>). Alterations in claudin-4 expression have been linked to hypermethylation, with inhibition of methylation enzymes promoting increases in cell polarization and transepithelial resistance (<xref rid="B9" ref-type="bibr">Boireau et al., 2007</xref>). Claudin-4 expression has also been studied in upper urinary tract carcinomas (<xref rid="B45" ref-type="bibr">Nakanishi et al., 2008</xref>). The protein is localized to the plasma membranes of neoplastic cells and is present in around three-quarters of tumor biopsies. Although claudin-4 has been linked to poor staging, no effect has been reported on disease-free and overall survival in this patient population (<xref rid="B45" ref-type="bibr">Nakanishi et al., 2008</xref>).</p><p>Gadelmoula et al. studied the expression of claudin-7 proteins and mRNA in urothelial bladder carcinoma patients (<xref rid="B20" ref-type="bibr">Gadelmoula et al., 2013</xref>). The authors demonstrated that claudin-7 is significantly downregulated compared to control specimens. Muscle-invasive tumors also exhibit less claudin-7 than their non-invasive counterparts; however, there was no difference in claudin-7 expression between different tumor grades (<xref rid="B20" ref-type="bibr">Gadelmoula et al., 2013</xref>). Then, Yamu&#x000e7; et al. examined the correlation between claudin-7 and patient outcomes (<xref rid="B77" ref-type="bibr">Yamu&#x000e7; et al., 2022</xref>). Although claudin-7 levels were different between genders, tumor stage, grade, and gender had no impact on the protein. Nevertheless, loss of claudin-7 was associated with tumor recurrence and poor overall survival. Contrarily, the utility of claudin-7 to differentiate between the histological grade of urothelial carcinomas has been reported, where high-grade tumors exhibit lower levels than low-grade ones (<xref rid="B69" ref-type="bibr">T&#x000f6;rzs&#x000f6;k et al., 2011</xref>). Claudin-7 is not associated with clinicopathologic factors, recurrence-free, or overall survival in urothelial carcinomas of the upper urinary tract (<xref rid="B45" ref-type="bibr">Nakanishi et al., 2008</xref>). The direct impact of claudin-7 on urothelial carcinomas is controversial; however, claudin-7 appears to play an antineoplastic role in this group of tumors. Further studies are needed to confirm the prognostic role of claudin-7 in urothelial carcinoma patients.</p><p>Awsare et al. studied the role of claudin-11 in human bladder carcinomas (<xref rid="B4" ref-type="bibr">Awsare et al., 2011</xref>). Claudin-11 mRNA levels were not different between carcinogenic and control samples; however, claudin-11 staining was less in the tumor samples when using immunohistochemistry. Forced expression of claudin-11 in bladder cancer cell lines blunted tumor invasion and increased cell matrix adhesion but increases tumor growth as well. Overall, alterations in the expression of claudins &#x02212;1, &#x02212;2, &#x02212;3, &#x02212;4, &#x02212;7, and &#x02212;11 have been reported in urothelial carcinomas (<xref rid="T1" ref-type="table">Table 1</xref>). Some of these claudins have shown prognostic value (<xref rid="T2" ref-type="table">Table 2</xref>), although further research is needed to validify these findings and clarify any contradictions.</p><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p>The changes of claudin levels in various neoplasms of the genitourinary tract.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Location</th><th align="center" rowspan="1" colspan="1">Type of tumor</th><th align="center" rowspan="1" colspan="1">Claudin isoform</th><th align="center" rowspan="1" colspan="1">Level of expression</th><th align="center" rowspan="1" colspan="1">Type of measured marker</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="9" align="center" colspan="1">Urinary Tract</td><td rowspan="5" align="center" colspan="1">Urothelial carcinoma of the lower tract</td><td align="center" rowspan="1" colspan="1">Claudin-1</td><td align="center" rowspan="1" colspan="1">&#x02191;<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>, &#x02193;<xref rid="Tfn2" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B67" ref-type="bibr">Sz&#x000e9;kely et al. (2011),</xref>
<xref rid="B57" ref-type="bibr">S&#x00103;ndulescu et al. (2022)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-2</td><td align="center" rowspan="1" colspan="1">&#x02191;<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">Protein and mRNA</td><td align="center" rowspan="1" colspan="1">
<xref rid="B69" ref-type="bibr">T&#x000f6;rzs&#x000f6;k et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-4</td><td align="center" rowspan="1" colspan="1">&#x02193;<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>, &#x02191;<xref rid="Tfn2" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">Protein and mRNA</td><td align="center" rowspan="1" colspan="1">
<xref rid="B9" ref-type="bibr">Boireau et al. (2007)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-7</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein and mRNA</td><td align="center" rowspan="1" colspan="1">
<xref rid="B20" ref-type="bibr">Gadelmoula et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-11</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein and mRNA</td><td align="center" rowspan="1" colspan="1">
<xref rid="B4" ref-type="bibr">Awsare et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Urothelial papillomas</td><td align="center" rowspan="1" colspan="1">Claudin-1</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B67" ref-type="bibr">Sz&#x000e9;kely et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Papillary urothelial neoplasms of low malignant potential</td><td align="center" rowspan="1" colspan="1">Claudin-1</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B67" ref-type="bibr">Sz&#x000e9;kely et al. (2011)</xref>
</td></tr><tr><td rowspan="2" align="center" colspan="1">Urothelial carcinoma of the upper tract</td><td align="center" rowspan="1" colspan="1">Claudin-3</td><td align="center" rowspan="1" colspan="1">&#x02191;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B45" ref-type="bibr">Nakanishi et al. (2008)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-4</td><td align="center" rowspan="1" colspan="1">&#x02191;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B45" ref-type="bibr">Nakanishi et al. (2008)</xref>
</td></tr><tr><td rowspan="7" align="center" colspan="1">Prostate</td><td rowspan="7" align="center" colspan="1">Prostatic adenocarcinoma</td><td align="center" rowspan="1" colspan="1">Claudin-1</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B59" ref-type="bibr">Sheehan et al. (2007),</xref>
<xref rid="B31" ref-type="bibr">Kind et al. (2020)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-2</td><td align="center" rowspan="1" colspan="1">&#x02191;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Coutinho-Camillo et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-3</td><td align="center" rowspan="1" colspan="1">&#x02191;; &#x02193;<xref rid="Tfn3" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Coutinho-Camillo et al. (2011),</xref>
<xref rid="B75" ref-type="bibr">Worst et al. (2017),</xref>
<xref rid="B81" ref-type="bibr">Ye et al. (2019)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-4</td><td align="center" rowspan="1" colspan="1">&#x02191;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B54" ref-type="bibr">Radi and Abd-Elazeem (2016)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-5</td><td align="center" rowspan="1" colspan="1">&#x02191;; &#x02193;<xref rid="Tfn4" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Coutinho-Camillo et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-7</td><td align="center" rowspan="1" colspan="1">&#x02193;<xref rid="Tfn4" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B59" ref-type="bibr">Sheehan et al. (2007)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-8</td><td align="center" rowspan="1" colspan="1">&#x02191;<xref rid="Tfn4" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">Protein and mRNA</td><td align="center" rowspan="1" colspan="1">
<xref rid="B3" ref-type="bibr">Ashikari et al. (2017)</xref>
</td></tr><tr><td rowspan="8" align="center" colspan="1">Kidney</td><td rowspan="4" align="center" colspan="1">Clear cell RCC</td><td align="center" rowspan="1" colspan="1">Claudin-1</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B18" ref-type="bibr">Fritzsche et al. (2008),</xref>
<xref rid="B61" ref-type="bibr">Shin et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-4</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B39" ref-type="bibr">Lechpammer et al. (2008)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-8</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein and mRNA</td><td align="center" rowspan="1" colspan="1">
<xref rid="B85" ref-type="bibr">Zhu et al. (2020)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-10</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein and mRNA</td><td align="center" rowspan="1" colspan="1">
<xref rid="B79" ref-type="bibr">Yang et al. (2021),</xref>
<xref rid="B80" ref-type="bibr">Yang et al. (2022)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Papillary RCC</td><td align="center" rowspan="1" colspan="1">Claudin-6</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B44" ref-type="bibr">Mikuteit et al. (2022)</xref>
</td></tr><tr><td rowspan="2" align="center" colspan="1">Chromophobe RCC</td><td align="center" rowspan="1" colspan="1">Claudin-6</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B17" ref-type="bibr">Erlmeier et al. (2023)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-7</td><td align="center" rowspan="1" colspan="1">&#x02191;</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">
<xref rid="B39" ref-type="bibr">Lechpammer et al. (2008),</xref>
<xref rid="B40" ref-type="bibr">Li et al. (2008),</xref>
<xref rid="B24" ref-type="bibr">Guti&#x000e9;rrez et al. (2018)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Unspecified RCC</td><td align="center" rowspan="1" colspan="1">Claudin-2</td><td align="center" rowspan="1" colspan="1">&#x02193;</td><td align="center" rowspan="1" colspan="1">Protein and RNA</td><td align="center" rowspan="1" colspan="1">
<xref rid="B35" ref-type="bibr">Kumar et al. (2021)</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="Tfn1"><label>
<sup>a</sup>
</label><p>High-grade.</p></fn><fn id="Tfn2"><label>
<sup>b</sup>
</label><p>Low-grade.</p></fn><fn id="Tfn3"><label>
<sup>c</sup>
</label><p>CRPC.</p></fn><fn id="Tfn4"><label>
<sup>d</sup>
</label><p>Conflicting data.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>TABLE 2</label><caption><p>The prognostic and diagnostic significance of claudins in genitourinary tract neoplasms.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Location</th><th align="center" rowspan="1" colspan="1">Type of tumor</th><th align="center" rowspan="1" colspan="1">Claudin isoform</th><th align="center" rowspan="1" colspan="1">Diagnostic/prognostic significance</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="3" align="center" colspan="1">Urinary tract</td><td align="center" rowspan="1" colspan="1">Urothelial carcinomas of the lower tract</td><td align="center" rowspan="1" colspan="1">Claudin-7</td><td align="center" rowspan="1" colspan="1">Tumor recurrence and poor survival</td><td align="center" rowspan="1" colspan="1">
<xref rid="B20" ref-type="bibr">Gadelmoula et al. (2013)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Papillary urothelial neoplasms of low malignant potential</td><td align="center" rowspan="1" colspan="1">Claudin-1</td><td align="center" rowspan="1" colspan="1">Poor recurrence-free survival</td><td align="center" rowspan="1" colspan="1">
<xref rid="B67" ref-type="bibr">Sz&#x000e9;kely et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Urothelial carcinoma of the upper tract</td><td align="center" rowspan="1" colspan="1">Claudin-3</td><td align="center" rowspan="1" colspan="1">Poor staging, grading, and pattern of growth</td><td align="center" rowspan="1" colspan="1">
<xref rid="B45" ref-type="bibr">Nakanishi et al. (2008)</xref>
</td></tr><tr><td rowspan="3" align="center" colspan="1">Prostate</td><td rowspan="3" align="center" colspan="1">Prostatic adenocarcinoma</td><td align="center" rowspan="1" colspan="1">Claudin-1</td><td align="center" rowspan="1" colspan="1">Reduced risk of PSA recurrence<xref rid="Tfn5" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">
<xref rid="B59" ref-type="bibr">Sheehan et al. (2007),</xref>
<xref rid="B31" ref-type="bibr">Kind et al. (2020)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-3</td><td align="center" rowspan="1" colspan="1">Distant metastasis; poor disease-free survival and time to progression<xref rid="Tfn6" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Coutinho-Camillo et al. (2011),</xref>
<xref rid="B75" ref-type="bibr">Worst et al. (2017),</xref>
<xref rid="B81" ref-type="bibr">Ye et al. (2019)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-4</td><td align="center" rowspan="1" colspan="1">Lymph node metastasis</td><td align="center" rowspan="1" colspan="1">
<xref rid="B54" ref-type="bibr">Radi and Abd-Elazeem (2016)</xref>
</td></tr><tr><td rowspan="8" align="center" colspan="1">Kidney</td><td rowspan="3" align="center" colspan="1">Clear cell RCC</td><td align="center" rowspan="1" colspan="1">Claudin-1</td><td align="center" rowspan="1" colspan="1">Increased levels associated with metastasis</td><td align="center" rowspan="1" colspan="1">
<xref rid="B18" ref-type="bibr">Fritzsche et al. (2008),</xref>
<xref rid="B61" ref-type="bibr">Shin et al. (2011)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-8</td><td align="center" rowspan="1" colspan="1">Poor overall survival</td><td align="center" rowspan="1" colspan="1">
<xref rid="B85" ref-type="bibr">Zhu et al. (2020)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-10</td><td align="center" rowspan="1" colspan="1">Poor disease-free and overall survival</td><td align="center" rowspan="1" colspan="1">
<xref rid="B79" ref-type="bibr">Yang et al. (2021),</xref>
<xref rid="B80" ref-type="bibr">Yang et al. (2022)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Papillary RCC</td><td align="center" rowspan="1" colspan="1">Claudin-1</td><td align="center" rowspan="1" colspan="1">Increased levels compared to chromophobe RCC</td><td align="center" rowspan="1" colspan="1">
<xref rid="B39" ref-type="bibr">Lechpammer et al. (2008)</xref>
</td></tr><tr><td rowspan="3" align="center" colspan="1">Chromophobe RCC</td><td rowspan="2" align="center" colspan="1">Claudin-7</td><td align="center" rowspan="1" colspan="1">Differentiates between other subtypes with 95% sensitivity and 92.3% specificity</td><td rowspan="2" align="center" colspan="1">
<xref rid="B13" ref-type="bibr">Choi et al. (2007),</xref>
<xref rid="B83" ref-type="bibr">Zhou et al. (2019)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Differentiates between papillary RCC, clear cell RCC, and oncocytomas with 94% sensitivity and 78% specificity, which increases to 100% when combining other markers</td></tr><tr><td align="center" rowspan="1" colspan="1">Claudin-8</td><td align="center" rowspan="1" colspan="1">Decreased levels compared to oncocytomas</td><td align="center" rowspan="1" colspan="1">
<xref rid="B39" ref-type="bibr">Lechpammer et al. (2008),</xref>
<xref rid="B30" ref-type="bibr">Kim et al. (2009),</xref>
<xref rid="B50" ref-type="bibr">Osunkoya et al. (2009)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Unspecified RCC</td><td align="center" rowspan="1" colspan="1">Claudin-2</td><td align="center" rowspan="1" colspan="1">Progression and poor survival</td><td align="center" rowspan="1" colspan="1">
<xref rid="B35" ref-type="bibr">Kumar et al. (2021)</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="Tfn5"><label>
<sup>a</sup>
</label><p>Conflicting data.</p></fn><fn id="Tfn6"><label>
<sup>b</sup>
</label><p>CRPC.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3"><title>3 Aberrant expression of claudins in prostate cancer</title><p>After analyzing over 17,000 prostate cancer specimens, Kind et al. found claudin-1 protein in 39% of cases, suggesting upregulation during malignant transformation compared to normal glandular cells (<xref rid="B31" ref-type="bibr">Kind et al., 2020</xref>). Two other studies, with smaller cohorts of 101 and 141 cases, also reported claudin-1 upregulation in 97% and 41% of tumors relative to normal prostatic glands (<xref rid="B59" ref-type="bibr">Sheehan et al., 2007</xref>; <xref rid="B72" ref-type="bibr">V&#x000e4;re et al., 2008</xref>). The differences in positive rates between these three studies likely stem from variations in staining protocols and evaluation criteria.</p><p>While claudin-1 expression is found normally in the prostate, there is conflicting data regarding its clinical utility. Four studies involving a total of 30, 48, 101, and 141 specimens have reported that the downregulation of claudin-1 is linked to unfavorable tumor characteristics, a poor prognosis, and/or biochemical recurrence (<xref rid="B59" ref-type="bibr">Sheehan et al., 2007</xref>; <xref rid="B72" ref-type="bibr">V&#x000e4;re et al., 2008</xref>; <xref rid="B58" ref-type="bibr">Seo et al., 2010</xref>; <xref rid="B66" ref-type="bibr">Sz&#x000e1;sz et al., 2010</xref>). In fact, through multivariate analysis, one study identified reduced claudin-1 expression as an independent predictor of tumor recurrence (<xref rid="B59" ref-type="bibr">Sheehan et al., 2007</xref>). Consistent with previous studies, Kind et al. found that claudin-1 upregulation is associated with favorable tumor features, low Gleason grade, and a reduced risk of PSA recurrence (<xref rid="B31" ref-type="bibr">Kind et al., 2020</xref>). Particularly, this was most relevant in ERG-positive prostate cancer where increased claudin-1 expression predicts a favorable prognosis (<xref rid="B31" ref-type="bibr">Kind et al., 2020</xref>). Nonetheless, multivariate analyses did not reveal an independent association of claudin-1 expression with prognosis (<xref rid="B31" ref-type="bibr">Kind et al., 2020</xref>).</p><p>However, these findings contradict the research by Krajevska et al. who reported claudin-1 expression in the basal cells of normal prostate glands, but its complete absence in luminal/glandular cells and in 98% of the analyzed cancer samples (<xref rid="B34" ref-type="bibr">Krajewska et al., 2007</xref>). This characteristic staining pattern of claudin-1 in the normal prostate was also described by Kind et al. (<xref rid="B31" ref-type="bibr">Kind et al., 2020</xref>). It is hypothesized that the loss of claudin-1 expression in prostate cancer could potentially indicate epithelial-mesenchymal transition (<xref rid="B42" ref-type="bibr">Medici et al., 2006</xref>; <xref rid="B78" ref-type="bibr">Yang et al., 2006</xref>).</p><p>In a study exploring the connection between abnormal expressions of claudin-1, claudin-3, claudin-4, and claudin-7 and prognostic factors in prostate cancer, Sheehan et al. determined that, like claudin-1, reduced claudin-7 expression correlated with poorly differentiated histological tumors (<xref rid="B59" ref-type="bibr">Sheehan et al., 2007</xref>). Conversely, they found that elevated levels of claudin-3 and claudin-4 were linked to advanced-stage tumors (<xref rid="B59" ref-type="bibr">Sheehan et al., 2007</xref>). In contrast, Camillo et al. demonstrated claudins-1 and -7 were equivocal, claudins-2, -3, and -5 were overexpressed, and claudin-4 was downregulated in prostate adenocarcinomas compared with normal samples (<xref rid="B14" ref-type="bibr">Coutinho-Camillo et al., 2011</xref>). However, even with all these alterations in claudin levels, they did not find any association with the main clinicopathological parameters.</p><p>Similar findings were observed by other studies regarding elevated claudin-3 and higher Gleason grade (<xref rid="B14" ref-type="bibr">Coutinho-Camillo et al., 2011</xref>; <xref rid="B75" ref-type="bibr">Worst et al., 2017</xref>). Specifically, Ye et al. found claudin-3 levels to be associated with distant metastasis in cancer cells, preoperative PSA levels, tumor diameter, and the pathological stage of the disease (<xref rid="B81" ref-type="bibr">Ye et al., 2019</xref>). Interestingly, in castration-resistant prostate cancer (CRPC), claudin-3 expression significantly decreased in samples from patients with high total Gleason scores (&#x02265;8) and locally advanced tumors, and this loss of expression was associated with worse disease-free survival and time to clinical progression (<xref rid="B49" ref-type="bibr">Orea et al., 2023</xref>). These findings strongly suggest that epigenetic silencing of claudin-3 is a common occurrence in CRPC, potentially serving as a valuable molecular marker for predicting the prognosis of prostate cancer patients and differentiating aggressive from indolent prostate tumors.</p><p>The observation by Sheehan et al. (<xref rid="B59" ref-type="bibr">Sheehan et al., 2007</xref>) regarding claudin-4 was similar to other studies (<xref rid="B37" ref-type="bibr">Landers et al., 2008</xref>; <xref rid="B72" ref-type="bibr">V&#x000e4;re et al., 2008</xref>; <xref rid="B66" ref-type="bibr">Sz&#x000e1;sz et al., 2010</xref>; <xref rid="B54" ref-type="bibr">Radi and Abd-Elazeem, 2016</xref>). One of those studies highlighted high claudin-4 expression as a poor prognosis biomarker due to its association with high tumor grade, lymphovascular invasion, positive lymph node metastasis, and high mean peritumoral lymphatic vessel density (<xref rid="B54" ref-type="bibr">Radi and Abd-Elazeem, 2016</xref>). Furthermore, Landers et al. found heightened expression in prostate cancer and metastatic prostate carcinoma compared to prostatic hyperplasia tissues (<xref rid="B37" ref-type="bibr">Landers et al., 2008</xref>). One noteworthy difference from the report of Sheehan et al. (<xref rid="B59" ref-type="bibr">Sheehan et al., 2007</xref>), Landers et al.&#x02019;s immunohistochemical analysis of claudin-4 was supported by a comparative evaluation of &#x003b1;-Methylacyl-CoA racemase (AMACR) and prostate-specific membrane antigen (PSMA)&#x02014;two well-established prostate cancer markers (<xref rid="B37" ref-type="bibr">Landers et al., 2008</xref>).</p><p>When examining sections containing high-grade prostatic intraepithelial neoplasia (HG-PIN) without associated invasive carcinoma, Landers et al. observed moderate claudin-4 intensity and low PSMA and AMACR levels (<xref rid="B37" ref-type="bibr">Landers et al., 2008</xref>). In contrast, HG-PIN cells in conjunction with invasive carcinoma displayed strong claudin-4 staining, but AMACR levels were low and PSMA levels were moderate (<xref rid="B37" ref-type="bibr">Landers et al., 2008</xref>). This suggests that claudin-4 may play a role in the early stages of prostate cancer development. The authors also discovered that lower-grade carcinomas exhibit higher claudin-4 expression compared to higher-grade carcinomas, with epithelial cells in benign glands surrounding the cancer sections displaying moderate to strong claudin-4 staining (<xref rid="B37" ref-type="bibr">Landers et al., 2008</xref>). This is consistent with loss of cellular organization as cancer progresses leading to a reduction in tight junction function, which aligns with alterations cellular polarity that enhance cellular mobility (<xref rid="B74" ref-type="bibr">Weinstein et al., 1976</xref>). Moreover, claudin-4 staining was strongly positive in most metastatic tumors, with no noticeable difference between specimens from patients receiving androgen suppression and those who were not (<xref rid="B37" ref-type="bibr">Landers et al., 2008</xref>). Also, there seemed to be no correlation between the metastatic site and the intensity of claudin-4 expression.</p><p>Generally, claudin-5 was found to be weakly expressed in prostate cancer compared to normal tissue, particularly in clinically poorly behaving carcinomas (<xref rid="B72" ref-type="bibr">V&#x000e4;re et al., 2008</xref>; <xref rid="B58" ref-type="bibr">Seo et al., 2010</xref>; <xref rid="B66" ref-type="bibr">Sz&#x000e1;sz et al., 2010</xref>). As for claudins &#x02212;7 and &#x02212;10, studies showed equivocal results (<xref rid="B72" ref-type="bibr">V&#x000e4;re et al., 2008</xref>; <xref rid="B66" ref-type="bibr">Sz&#x000e1;sz et al., 2010</xref>; <xref rid="B14" ref-type="bibr">Coutinho-Camillo et al., 2011</xref>). Nonetheless, one study found an association between low expression of claudin-7 and higher tumor grade (<xref rid="B59" ref-type="bibr">Sheehan et al., 2007</xref>). To note, two forms of claudin-7 exist, a full-length form of CLDN-7 with 211 amino-acid residues and a C-terminal truncated form with 158 amino-acid residues, both of which were found to regulate the expression of PSA (<xref rid="B82" ref-type="bibr">Zheng et al., 2003</xref>). Hence, it can be of interest for future studies to explore the difference in expression of both forms of claudin-7 and correlate it to prognostic markers.</p><p>While Sz&#x000e1;sz et al. observed a significant decrease in claudin-8 expression, it did not have any clinical correlation (<xref rid="B66" ref-type="bibr">Sz&#x000e1;sz et al., 2010</xref>). On the contrary, Ashikari et al. indicated that claudin 8 was overexpressed in prostate cancer clinical samples compared to benign tissues (<xref rid="B3" ref-type="bibr">Ashikari et al., 2017</xref>). Moreover, their findings demonstrate that claudin-8 not only regulates intracellular signal transduction and stabilizes the cytoskeleton but also operates as an androgen receptor downstream signal, collectively contributing to the advancement of prostate cancer. Collectively, several claudins are altered in prostate cancers, among which several have clinical significance (<xref rid="T1" ref-type="table">Table 1</xref>).</p></sec><sec id="s4"><title>4 Aberrant expression of claudins in renal cell carcinomas</title><p>Kidney neoplasms are the sixth and 10th most common cancers in men and women, respectively (<xref rid="B6" ref-type="bibr">Bahadoram et al., 2022</xref>). RCC, the most common type of renal tumors, constitutes approximately 3% of all adult malignancies (<xref rid="B55" ref-type="bibr">Rini et al., 2009</xref>). RCCs are generally divided into five subtypes: clear cell, papillary, chromophobe, collecting duct, and unclassified, among which the first three constitute the majority of RCCs (<xref rid="B70" ref-type="bibr">Truong and Shen, 2011</xref>). Although advances in the medical and surgical management of RCCs have been made (<xref rid="B55" ref-type="bibr">Rini et al., 2009</xref>; <xref rid="B8" ref-type="bibr">Bazarbashi et al., 2023</xref>), the outcomes associated with the tumor remain relatively poor (<xref rid="B5" ref-type="bibr">Badran et al., 2020</xref>). Additionally, differentiating between different subtypes of RCC is still difficult. Claudins have been used to fill these gaps as diagnostic, prognostic, and therapeutic tools in RCCs. In this section, we will summarize the evidence discussing these applications (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p>Claudin-1 is expressed in renal biopsies as a membranous pattern, mostly in the Bowman membrane and, to a lesser degree, the epithelium of the distal tubules and collecting ducts (<xref rid="B18" ref-type="bibr">Fritzsche et al., 2008</xref>; <xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>). On the other hand, the protein is only seen in one-third of RCC samples (<xref rid="B18" ref-type="bibr">Fritzsche et al., 2008</xref>). Claudin-1 mainly localizes at the plasma membrane and sometimes in the cytoplasm of neoplastic cells. Specifically, three-quarters of papillary RCCs express claudin-1, while only a quarter of clear cell RCCs exhibit the protein (<xref rid="B18" ref-type="bibr">Fritzsche et al., 2008</xref>). In clear cell RCC, claudin-1 expression is associated with metastasis and high-grade tumors (<xref rid="B18" ref-type="bibr">Fritzsche et al., 2008</xref>; <xref rid="B61" ref-type="bibr">Shin et al., 2011</xref>). Claudin-1 expression correlates with poor disease-specific survival only in asymptomatic clear cell RCC patients but not in all patients (<xref rid="B18" ref-type="bibr">Fritzsche et al., 2008</xref>). However, the protein is associated with increased postoperative distant metastasis in clear cell RCC patients (<xref rid="B61" ref-type="bibr">Shin et al., 2011</xref>). Contrarily, claudin-1 expression is associated with improved clinicopathologic characteristics in papillary RCC, but not survival (<xref rid="B18" ref-type="bibr">Fritzsche et al., 2008</xref>). Claudin-1 immunohistochemistry can also be used to differentiate papillary RCC from its chromophobe counterpart, which exhibits weak expression (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>).</p><p>Claudin-2 is significantly reduced in RCC samples, and loss of the protein is associated with tumor progression and poor survival (<xref rid="B35" ref-type="bibr">Kumar et al., 2021</xref>). Claudin-2 overexpression inhibits mesenchymal plasticity, tumorigenic abilities, and tumor growth in murine models (<xref rid="B35" ref-type="bibr">Kumar et al., 2021</xref>). Claudin-3 is strongly expressed in the distal tubules and collecting ducts and weakly in the glomeruli and proximal tubules of normal renal samples (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>). Claudin-3 expression varies from moderate to strong in papillary, chromophobe, and clear cell RCCs (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>). Claudin-3 is predominantly seen in lower grades of clear cell RCCs and is not associated with tumor grade in other subtypes (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>). Although claudin-3 is associated with poor survival in univariate analysis, multivariate analysis diminishes this effect (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>).</p><p>Strong expression of claudin-4 in normal renal samples can be seen in the cell membrane and cytoplasm of distal tubules and collecting ducts cells (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>; <xref rid="B52" ref-type="bibr">Owari et al., 2020</xref>). Claudin-4 is not associated with histological grade or staging in RCC patients (<xref rid="B52" ref-type="bibr">Owari et al., 2020</xref>). Chromophobe RCCs also exhibit moderate to strong claudin-4 expression, while only half of clear cell RCCs express the protein (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>). Similar to claudin-3, strong expression of claudin-4 is associated with poor survival in clear cell RCC using univariate but not multivariate analysis (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>).</p><p>Studies reporting the presence of claudin-6 in RCCs are limited. Mikuteit et al. assessed the prognostic role of the protein in papillary RCCs (<xref rid="B44" ref-type="bibr">Mikuteit et al., 2022</xref>). Claudin-6 was present in around one-fifth of patients with type 1 and type 2 papillary RCC. Expression of the protein had no impact on survival in these patients. Then, Erlmeier et al. aimed to assess the same in chromophobe RCC patients (<xref rid="B17" ref-type="bibr">Erlmeier et al., 2023</xref>). Claudin-6 was only seen in 12.3% of chromophobe tumor samples. Like papillary RCC, claudin-6 expression was not correlated with overall survival (<xref rid="B17" ref-type="bibr">Erlmeier et al., 2023</xref>). To the best of the authors&#x02019; knowledge, these are the only available reports of claudin-6 expression in RCC samples. Future studies should aim to define its role in clear cell RCCs and other subtypes.</p><p>In normal renal samples, claudin-7 is only expressed in the distal convoluted tubules and distal collecting ducts (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>). Membranous claudin-7 expression can be seen in the majority of chromophobe and, to a lesser extent, papillary RCCs (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>; <xref rid="B40" ref-type="bibr">Li et al., 2008</xref>; <xref rid="B24" ref-type="bibr">Guti&#x000e9;rrez et al., 2018</xref>). Claudin-7 has proven useful as a diagnostic tool to differentiate between different renal tumors, especially oncocytomas and chromophobe RCC (<xref rid="B50" ref-type="bibr">Osunkoya et al., 2009</xref>; <xref rid="B48" ref-type="bibr">Ohe et al., 2012</xref>). The protein has a sensitivity and specificity of 95% and 92.3% in discriminating between chromophobe RCC and other RCC subtypes (<xref rid="B13" ref-type="bibr">Choi et al., 2007</xref>). When differentiating chromophobe tumors from papillary RCCs, clear cell RCCs, and oncocytoma, the protein demonstrates a sensitivity and specificity of 94% and 78%, respectively (<xref rid="B83" ref-type="bibr">Zhou et al., 2019</xref>). Specificity can be further increased to 100% when combining claudin-7 with additional markers CD117 and CK7 (<xref rid="B83" ref-type="bibr">Zhou et al., 2019</xref>).</p><p>The prognostic implications of claudin-7 expression are controversial. In a study of 120 clear cell RCC patients, reduced claudin-7 expression predicted poor staging and survival (<xref rid="B41" ref-type="bibr">Li et al., 2018</xref>). In line with these findings, forced overexpression of claudin-7 triggers neoplastic cell apoptosis, blunts proliferation, and inhibits tumor invasion and migration (<xref rid="B41" ref-type="bibr">Li et al., 2018</xref>). However, another study by Shin et al. found no association between the protein with disease-free and overall survival (<xref rid="B61" ref-type="bibr">Shin et al., 2011</xref>). Despite the clear diagnostic practicality of using claudin-7, more investigations are needed into its prognostic role.</p><p>Similar to claudin-7, claudin-8 exhibits membranous staining patterns in the distal tubules and collecting ducts (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>). Clear cell RCCs exhibit lower claudin-8 mRNA and protein levels than normal tissue samples (<xref rid="B85" ref-type="bibr">Zhu et al., 2020</xref>). The protein appears to play a role in facilitating pro-neoplastic effects. Zhu et al. studied the effects of claudin-8 on clear cell RCC progression and its prognostic value (<xref rid="B85" ref-type="bibr">Zhu et al., 2020</xref>). Claudin overexpression attenuated tumor invasion, migration, and proliferation <italic>via</italic> its modulatory effects on epithelial-to-mesenchymal transition and Akt pathways (<xref rid="B85" ref-type="bibr">Zhu et al., 2020</xref>). Low claudin-8 levels were also independently associated with poor overall survival in their group of patients (<xref rid="B85" ref-type="bibr">Zhu et al., 2020</xref>). Furthermore, chromophobe RCCs demonstrate significantly reduced cytoplasmic staining of claudin-8 than oncocytomas, highlighting its diagnostic utility (<xref rid="B39" ref-type="bibr">Lechpammer et al., 2008</xref>; <xref rid="B30" ref-type="bibr">Kim et al., 2009</xref>; <xref rid="B50" ref-type="bibr">Osunkoya et al., 2009</xref>). Whether claudin-8 has any prognostic value in other RCC subtypes remains unstudied.</p><p>Claudin-10 expression is significantly blunted in clear cell RCC (<xref rid="B79" ref-type="bibr">Yang et al., 2021</xref>). Increased claudin-10 mRNA expression is independently associated with longer disease-free and overall survival in clear cell RCC patients (<xref rid="B79" ref-type="bibr">Yang et al., 2021</xref>; <xref rid="B80" ref-type="bibr">Yang et al., 2022</xref>). Claudin-10 overexpression induces apoptosis and inhibits migration, invasion, and proliferation by promoting mitochondrial dysfunction (<xref rid="B80" ref-type="bibr">Yang et al., 2022</xref>). Moreover, claudin-10 is associated with increased dendritic cell and na&#x000ef;ve and memory T-cell tumor infiltration, which has been linked with better outcomes (<xref rid="B79" ref-type="bibr">Yang et al., 2021</xref>). Aberrant expression of claudins &#x02212;14, &#x02212;17, &#x02212;19, and &#x02212;22 has also been reported in RCCs (<xref rid="B43" ref-type="bibr">Men et al., 2015</xref>; <xref rid="B62" ref-type="bibr">Singh and Vinod, 2020</xref>); however, reports about these proteins are still extremely limited.</p></sec><sec id="s5"><title>5 Mechanisms causing aberrant expression of claudins in GU cancers</title><p>The mechanisms underlying aberrant expression of claudins in GU carcinomas are not completely understood. Nevertheless, several mechanisms have been studied and reported (<xref rid="F2" ref-type="fig">Figure 2</xref>). Epigenetic modifications&#x02013;mainly through DNA methylation&#x02013;appear to play a crucial role in the induction of aberrant expression. For example, the claudin-4 gene is hypermethylated in bladder carcinomas (<xref rid="B9" ref-type="bibr">Boireau et al., 2007</xref>). Treatment with DNA methyltransferase inhibitors reverses the effects of <italic>CLDN4</italic> methylation, increasing cell polarization and transepithelial resistance (<xref rid="B9" ref-type="bibr">Boireau et al., 2007</xref>). In RCC, promoter hypermethylation is associated with reduced claudin-7 mRNA and protein expression (<xref rid="B41" ref-type="bibr">Li et al., 2018</xref>). Hypermethylation of the claudin-7 promoter is associated with advanced tumors and poor survival in these patients (<xref rid="B41" ref-type="bibr">Li et al., 2018</xref>). Furthermore, hypermethylation of claudin &#x02212;8, &#x02212;9, &#x02212;10, &#x02212;14, &#x02212;19, and &#x02212;22 promoters has been reported in papillary RCC (<xref rid="B62" ref-type="bibr">Singh and Vinod, 2020</xref>).</p><fig position="float" id="F2"><label>FIGURE 2</label><caption><p>Alterations relating to &#x00394;Np63 and CRIM-1 increase claudin-1 levels, which promote tumor invasion and epithelial-mesenchymal transition (EMT). Claudins-4 and -7 are modulated by DNA methylation. These mechanisms can be targeted therapeutically through DNA methyltransferase inhibitors and infliximab, which have shown promising results.</p></caption><graphic xlink:href="fcell-11-1308082-g002" position="float"/></fig><p>Transmembrane proteins, specifically cysteine-rich motor neuron-1 (CRIM-1), also regulate the expression of claudins in GU cancers. The CRIM-1 protein is highly expressed in the kidney and placenta cells (<xref rid="B33" ref-type="bibr">Kolle et al., 2000</xref>). Ogasawara et al. analyzed the effects of CRIM-1 on proliferation, malignant transformation, and claudin expression in RCCs (<xref rid="B47" ref-type="bibr">Ogasawara et al., 2018</xref>). The authors demonstrated that decreased expression of CRIM-1 does not impact tumor growth or proliferation. However, the authors revealed that under-expression of CRIM-1 increases tumor invasion and epithelial-mesenchymal transition by reducing E-cadherin expression and increasing claudin-1 and MMP-2 and -9 expression. Expression of CRIM-1 was blunted by tumor necrosis factor (TNF)-&#x00251;, indicating a potential therapeutic value of targeting this pathway. In line with this, treatment with infliximab, an anti-TNF-&#x00251; antibody, resulted in 16% of RCC patients achieving partial response and 16% achieving stable disease in a phase II trial (<xref rid="B25" ref-type="bibr">Harrison et al., 2007</xref>). Nevertheless, the efficacy of infliximab in RCC remains controversial and further studies are still needed (<xref rid="B38" ref-type="bibr">Larkin et al., 2010</xref>).</p><p>The p63 gene, a member of the tumor suppressor p53 family, has two different promotes which produce isotypes that contain or lack (&#x00394;N) an NH2-terminus (<xref rid="B12" ref-type="bibr">Chen et al., 2018</xref>). Studies have demonstrated the regulatory effects of p63 on claudin expression in epithelial cells (<xref rid="B32" ref-type="bibr">Kojima et al., 2017</xref>). However, this relationship remains unclear in GU cancers. The &#x00394;Np63 isotype is overexpressed in bladder cell carcinomas (<xref rid="B53" ref-type="bibr">Park et al., 2000</xref>; <xref rid="B28" ref-type="bibr">Jing et al., 2013</xref>). In bladder carcinoma cell lines, &#x00394;Np63 promotes tumor invasion and metastasis through overexpression of claudin-1, and knockdown of the isotype blunts these effects (<xref rid="B28" ref-type="bibr">Jing et al., 2013</xref>). Conclusively, epigenetics, transmembrane proteins, and the p63 gene modulate claudin expression in various GU cancers. Studies are still limited in this regard and more investigations are needed to implicate additional signaling pathways.</p></sec><sec id="s6"><title>6 The therapeutic value of claudins in GU cancers</title><p>Several therapeutic avenues targeting claudins have been explored in the context of GU carcinomas. Firstly, claudin expression has been used to tailor management and predict the response of patients to certain drugs. Despite claudin-low bladder tumors expressing high levels of immune gene signatures, they also exhibit high levels of immune checkpoint molecules (<xref rid="B29" ref-type="bibr">Kardos et al., 2016</xref>). These findings have led some to hypothesize that molecular subtypes can be used to predict immunotherapeutic responses (<xref rid="B29" ref-type="bibr">Kardos et al., 2016</xref>). In line with these findings, the PURE-01 study assessed the effects of preoperative pembrolizumab on post-cystectomy remission times. The study revealed that claudin-low muscle-invasive bladder cancer patients exhibit longer event-free survival than other patient categories after pembrolizumab and radical cystectomy (<xref rid="B7" ref-type="bibr">Bandini et al., 2020</xref>; <xref rid="B46" ref-type="bibr">Necchi et al., 2020</xref>).</p><p>Antibodies targeting different claudins have also begun emerging. Among them, Kuwada et al. developed a rat antibody targeting the extracellular domain of the claudin-4 protein (<xref rid="B36" ref-type="bibr">Kuwada et al., 2015</xref>). The antibody inhibited bladder cell growth and invasion and promoted apoptosis (<xref rid="B36" ref-type="bibr">Kuwada et al., 2015</xref>). Furthermore, the antibody increased cellular permeability to cisplatin, inhibiting tumor growth and improving survival in mice models (<xref rid="B36" ref-type="bibr">Kuwada et al., 2015</xref>).</p><p>Bufalin&#x02013;a steroid obtained from toads&#x02013;exhibits antineoplastic effects in several tumors, such as gastrointestinal, breast, and lung cancers (<xref rid="B27" ref-type="bibr">Jiang et al., 2010</xref>; <xref rid="B68" ref-type="bibr">Takai et al., 2012</xref>). Bufalin inhibits bladder cancer migration and invasion by reducing expression of several claudins and MMPs, possibly through phosphorylation of the extracellular signal-regulated protein kinase (ERK) pathway (<xref rid="B26" ref-type="bibr">Hong et al., 2013</xref>). Diallyl trisulfide&#x02013;a compound extracted from garlic&#x02013;also exhibits antineoplastic similar effects to bufalin in bladder cancer cell lines (<xref rid="B60" ref-type="bibr">Shin et al., 2013</xref>). Finally, the <italic>Clostridium perfringens</italic> enterotoxin (CPE), which binds to claudins &#x02212;3 and &#x02212;4, induces cell death in low and moderately aggressive bladder cancer cells (<xref rid="B19" ref-type="bibr">Gabig et al., 2016</xref>). The non-toxic fragment of CPE also increases cell sensitivity to mitomycin C and dasatinib (<xref rid="B19" ref-type="bibr">Gabig et al., 2016</xref>). Claudins have provided promising therapeutic value in both clinical and preclinical studies. Nevertheless, human studies are needed to determine whether direct targeting of claudins is impactful in clinical settings.</p></sec><sec id="s7"><title>7 Conclusion and future perspectives</title><p>GU cancers are among the most prevalent neoplasms worldwide. Despite several advances in diagnosis and therapeutics, poor outcomes are seen in a large portion of patients. Claudins have piqued the interest of the scientific community due to the aberrant expression seen in a wide spectrum of tumors. Several studies have expanded on this in the context of GU cancers, such as those in the bladder, prostate, and kidneys. Abnormal expression of claudins, such as claudins &#x02212;1 and &#x02212;7, has been linked to clinicopathological characteristics and prognosis in GU cancer patients. Furthermore, claudins have been used to histologically differentiate between different types of renal tumors, specifically chromophobe RCCs and oncocytomas.</p><p>This manuscript also summarizes the different pathways involved in promoting aberrant claudin expression. DNA methylation impacts the expression of various claudins, and such effects have been reported in several types of GU tumors. TNF-&#x00251; modulates the expression of claudin-1 and promotes tumor invasion. Finally, the &#x00394;Np63 isotype exerts pro-neoplastic effects by increasing claudin-1 expression in bladder cancer cells.</p><p>In the realm of claudin research within GU neoplasms, there lies a fertile ground for future research, particularly in unraveling the molecular mechanisms of aberrant expression of claudins. The interactions of claudins with other tight junction proteins and their roles in cellular signaling pathways are pivotal areas that demand deeper investigation, especially concerning their contribution to tumorigenesis and metastasis. With the advent of cutting-edge technologies such as CRISPR/Cas9 gene editing and advanced imaging, new dimensions of claudin behavior in cancer cells can be unveiled, potentially leading to more accurate disease models and real-time visualization of tumor progression. Molecular targeted magnetic resonance imaging is capable of detecting claudin-2 in interstitial cystitis mouse models (<xref rid="B64" ref-type="bibr">Smith et al., 2020</xref>). Similar imaging techniques could be utilized in the future to accurately detect and track claudin-positive GU neoplasms.</p><p>The field also grapples with unresolved questions, notably the heterogeneity of claudin expression in various cancer subtypes and stages, and its implications on prognosis and therapeutic response. The exploration of claudin-based therapeutics, despite its promising outlook, remains in its nascent stage, requiring more rigorous clinical trials and research to ascertain its efficacy and safety. Looking ahead, the integration of claudins into personalized medicine emerges as a critical frontier. Developing diagnostic tools and treatment strategies based on individual claudin profiles could revolutionize patient care. Additionally, the synergy of claudin-targeted therapies with established treatment modalities like chemotherapy, immunotherapy, or radiation presents a promising avenue for enhancing treatment outcomes and overcoming resistance.</p></sec></body><back><ack><p>The figures in this manuscript were made using <ext-link xlink:href="http://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>.</p></ack><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>TA: Writing&#x02013;original draft. NA: Writing&#x02013;original draft. BS: Visualization, Writing&#x02013;original draft. AO: Conceptualization, Writing&#x02013;review and editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R.</given-names></name><name><surname>Chaturvedi</surname><given-names>R.</given-names></name><name><surname>Olivares-Villag&#x000f3;mez</surname><given-names>D.</given-names></name><name><surname>Habib</surname><given-names>T.</given-names></name><name><surname>Asim</surname><given-names>M.</given-names></name><name><surname>Shivesh</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Targeted colonic claudin-2 expression renders resistance to epithelial injury, induces immune suppression, and protects from colitis</article-title>. <source>Mucosal Immunol.</source>
<volume>7</volume> (<issue>6</issue>), <fpage>1340</fpage>&#x02013;<lpage>1353</lpage>. <pub-id pub-id-type="doi">10.1038/mi.2014.21</pub-id>
<pub-id pub-id-type="pmid">24670427</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arabi</surname><given-names>T. Z.</given-names></name><name><surname>Algheryafi</surname><given-names>L. A.</given-names></name><name><surname>Alodah</surname><given-names>N. A.</given-names></name><name><surname>Enabi</surname><given-names>H. M. K.</given-names></name><name><surname>Alshehry</surname><given-names>A. A.</given-names></name><name><surname>Ouban</surname><given-names>A.</given-names></name></person-group> (<year>2023</year>). <article-title>Aberrant expression of claudins in head and neck carcinomas and their prognostic and therapeutic value: a narrative review</article-title>. <source>Cancers</source>
<volume>15</volume> (<issue>17</issue>), <fpage>4208</fpage>. <pub-id pub-id-type="doi">10.3390/cancers15174208</pub-id>
<pub-id pub-id-type="pmid">37686483</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashikari</surname><given-names>D.</given-names></name><name><surname>Takayama</surname><given-names>K.-i.</given-names></name><name><surname>Obinata</surname><given-names>D.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Inoue</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>CLDN8, an androgen-regulated gene, promotes prostate cancer cell proliferation and migration</article-title>. <source>Cancer Sci.</source>
<volume>108</volume> (<issue>7</issue>), <fpage>1386</fpage>&#x02013;<lpage>1393</lpage>. <pub-id pub-id-type="doi">10.1111/cas.13269</pub-id>
<pub-id pub-id-type="pmid">28474805</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Awsare</surname><given-names>N. S.</given-names></name><name><surname>Martin</surname><given-names>T. A.</given-names></name><name><surname>Haynes</surname><given-names>M. D.</given-names></name><name><surname>Matthews</surname><given-names>P. N.</given-names></name><name><surname>Jiang</surname><given-names>W. G.</given-names></name></person-group> (<year>2011</year>). <article-title>Claudin-11 decreases the invasiveness of bladder cancer cells</article-title>. <source>Oncol. Rep.</source>
<volume>25</volume> (<issue>6</issue>), <fpage>1503</fpage>&#x02013;<lpage>1509</lpage>. <pub-id pub-id-type="doi">10.3892/or.2011.1244</pub-id>
<pub-id pub-id-type="pmid">21468549</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Badran</surname><given-names>A.</given-names></name><name><surname>Elshenawy</surname><given-names>M. A.</given-names></name><name><surname>Shahin</surname><given-names>A.</given-names></name><name><surname>Aljubran</surname><given-names>A.</given-names></name><name><surname>Alzahrani</surname><given-names>A.</given-names></name><name><surname>Eldali</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Efficacy and prognostic factors of sunitinib as first-line therapy for patients with metastatic renal cell carcinoma in an arab population</article-title>. <source>JCO Glob. Oncol.</source>
<volume>6</volume> (<issue>6</issue>), <fpage>19</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1200/jgo.19.00111</pub-id>
<pub-id pub-id-type="pmid">32031432</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bahadoram</surname><given-names>S.</given-names></name><name><surname>Davoodi</surname><given-names>M.</given-names></name><name><surname>Hassanzadeh</surname><given-names>S.</given-names></name><name><surname>Bahadoram</surname><given-names>M.</given-names></name><name><surname>Barahman</surname><given-names>M.</given-names></name><name><surname>Mafakher</surname><given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment</article-title>. <source>G. Ital. Nefrol.</source>
<volume>39</volume> (<issue>3</issue>), <fpage>2022-vol3</fpage>.</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bandini</surname><given-names>M.</given-names></name><name><surname>Gibb</surname><given-names>E. A.</given-names></name><name><surname>Gallina</surname><given-names>A.</given-names></name><name><surname>Raggi</surname><given-names>D.</given-names></name><name><surname>Marandino</surname><given-names>L.</given-names></name><name><surname>Bianchi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study&#x02606;</article-title>. <source>Ann. Oncol.</source>
<volume>31</volume> (<issue>12</issue>), <fpage>1755</fpage>&#x02013;<lpage>1763</lpage>. <pub-id pub-id-type="doi">10.1016/j.annonc.2020.09.011</pub-id>
<pub-id pub-id-type="pmid">32979511</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bazarbashi</surname><given-names>S.</given-names></name><name><surname>Alzahrani</surname><given-names>A.</given-names></name><name><surname>Aljubran</surname><given-names>A.</given-names></name><name><surname>Elshenawy</surname><given-names>M.</given-names></name><name><surname>Gad</surname><given-names>A. M.</given-names></name><name><surname>Maraiki</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Combining sunitinib and bevacizumab for the management of advanced renal cell carcinoma: a phase I/II trial</article-title>. <source>Oncologist</source>
<volume>28</volume> (<issue>5</issue>), <fpage>e254</fpage>&#x02013;<lpage>e262</lpage>. <pub-id pub-id-type="doi">10.1093/oncolo/oyac261</pub-id>
<pub-id pub-id-type="pmid">36648325</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boireau</surname><given-names>S.</given-names></name><name><surname>Buchert</surname><given-names>M.</given-names></name><name><surname>Samuel</surname><given-names>M. S.</given-names></name><name><surname>Pannequin</surname><given-names>J.</given-names></name><name><surname>Ryan</surname><given-names>J. L.</given-names></name><name><surname>Choquet</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma</article-title>. <source>Carcinogenesis</source>
<volume>28</volume> (<issue>2</issue>), <fpage>246</fpage>&#x02013;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgl120</pub-id>
<pub-id pub-id-type="pmid">16829686</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Siegel</surname><given-names>R. L.</given-names></name><name><surname>Torre</surname><given-names>L. A.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA A Cancer J. Clin.</source>
<volume>68</volume> (<issue>6</issue>), <fpage>394</fpage>&#x02013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21492</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Bu</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Expression of tight junction proteins is altered in bladder cancer</article-title>. <source>Anal. Cell. Pathol.</source>
<volume>2020</volume>, <fpage>6341256</fpage>&#x02013;<lpage>6341258</lpage>. <pub-id pub-id-type="doi">10.1155/2020/6341256</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>Z.-X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>A double dealing tale of p63: an oncogene or a tumor suppressor</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>75</volume> (<issue>6</issue>), <fpage>965</fpage>&#x02013;<lpage>973</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-017-2666-y</pub-id>
<pub-id pub-id-type="pmid">28975366</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y. D.</given-names></name><name><surname>Kim</surname><given-names>K. S.</given-names></name><name><surname>Ryu</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>Y.</given-names></name><name><surname>Cho</surname><given-names>N. H.</given-names></name><name><surname>Rha</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma</article-title>. <source>J. Korean Med. Sci.</source>
<volume>22</volume> (<issue>2</issue>), <fpage>305</fpage>&#x02013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.3346/jkms.2007.22.2.305</pub-id>
<pub-id pub-id-type="pmid">17449941</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coutinho-Camillo</surname><given-names>C. M.</given-names></name><name><surname>Louren&#x000e7;o</surname><given-names>S. V.</given-names></name><name><surname>da Fonseca</surname><given-names>F. P.</given-names></name><name><surname>Soares</surname><given-names>F. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Claudin expression is dysregulated in prostate adenocarcinomas but does not correlate with main clinicopathological parameters</article-title>. <source>Pathology</source>
<volume>43</volume> (<issue>2</issue>), <fpage>143</fpage>&#x02013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1097/PAT.0b013e3283428099</pub-id>
<pub-id pub-id-type="pmid">21233676</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalghi</surname><given-names>M. G.</given-names></name><name><surname>Montalbetti</surname><given-names>N.</given-names></name><name><surname>Carattino</surname><given-names>M. D.</given-names></name><name><surname>Apodaca</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>The urothelium: life in a liquid environment</article-title>. <source>Physiol. Rev.</source>
<volume>100</volume> (<issue>4</issue>), <fpage>1621</fpage>&#x02013;<lpage>1705</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00041.2019</pub-id>
<pub-id pub-id-type="pmid">32191559</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elsen</surname><given-names>S.</given-names></name><name><surname>Lerut</surname><given-names>E.</given-names></name><name><surname>Van Cleynenbreugel</surname><given-names>B.</given-names></name><name><surname>van der Aa</surname><given-names>F.</given-names></name><name><surname>van Poppel</surname><given-names>H.</given-names></name><name><surname>de Witte</surname><given-names>P. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Biodistribution of Evans blue in an orthotopic AY-27 rat bladder urothelial cell carcinoma model: implication for the improved diagnosis of non-muscle-invasive bladder cancer (NMIBC) using dye-guided white-light cystoscopy</article-title>. <source>BJU Int.</source>
<volume>116</volume> (<issue>3</issue>), <fpage>468</fpage>&#x02013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1111/bju.13113</pub-id>
<pub-id pub-id-type="pmid">25754262</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erlmeier</surname><given-names>F.</given-names></name><name><surname>Zsch&#x000e4;bitz</surname><given-names>S.</given-names></name><name><surname>Mikuteit</surname><given-names>M.</given-names></name><name><surname>Autenrieth</surname><given-names>M.</given-names></name><name><surname>Weichert</surname><given-names>W.</given-names></name><name><surname>Hartmann</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>The role of claudin-6 in chromophobe renal cell carcinoma</article-title>. <source>Histol. Histopathol.</source>
<volume>38</volume> (<issue>4</issue>), <fpage>403</fpage>&#x02013;<lpage>407</lpage>. <pub-id pub-id-type="doi">10.14670/hh-18-520</pub-id>
<pub-id pub-id-type="pmid">36128931</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fritzsche</surname><given-names>F. R.</given-names></name><name><surname>Oelrich</surname><given-names>B.</given-names></name><name><surname>Johannsen</surname><given-names>M.</given-names></name><name><surname>Kristiansen</surname><given-names>I.</given-names></name><name><surname>Moch</surname><given-names>H.</given-names></name><name><surname>Jung</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas</article-title>. <source>Clin. Cancer Res.</source>
<volume>14</volume> (<issue>21</issue>), <fpage>7035</fpage>&#x02013;<lpage>7042</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-08-0855</pub-id>
<pub-id pub-id-type="pmid">18981000</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gabig</surname><given-names>T. G.</given-names></name><name><surname>Waltzer</surname><given-names>W. C.</given-names></name><name><surname>Whyard</surname><given-names>T.</given-names></name><name><surname>Romanov</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>
<italic>Clostridium perfringens</italic> enterotoxin as a potential drug for intravesical treatment of bladder cancer</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>478</volume> (<issue>2</issue>), <fpage>887</fpage>&#x02013;<lpage>892</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.08.046</pub-id>
<pub-id pub-id-type="pmid">27520378</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gadelmoula</surname><given-names>M.</given-names></name><name><surname>Fukumori</surname><given-names>T.</given-names></name><name><surname>Nakatsuji</surname><given-names>H.</given-names></name><name><surname>Elgammal</surname><given-names>M.</given-names></name><name><surname>Toida</surname><given-names>K.</given-names></name><name><surname>Kanayama</surname><given-names>H.-O.</given-names></name></person-group> (<year>2013</year>). <article-title>Down-regulated claudin-7 immunoexpression in urothelial carcinoma of the urinary bladder</article-title>. <source>Arab J. Urology</source>
<volume>11</volume> (<issue>2</issue>), <fpage>182</fpage>&#x02013;<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1016/j.aju.2013.04.006</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gandaglia</surname><given-names>G.</given-names></name><name><surname>Leni</surname><given-names>R.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Fleshner</surname><given-names>N.</given-names></name><name><surname>Freedland</surname><given-names>S. J.</given-names></name><name><surname>Kibel</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Epidemiology and prevention of prostate cancer</article-title>. <source>Eur. Urol. Oncol.</source>
<volume>4</volume> (<issue>6</issue>), <fpage>877</fpage>&#x02013;<lpage>892</lpage>. <pub-id pub-id-type="doi">10.1016/j.euo.2021.09.006</pub-id>
<pub-id pub-id-type="pmid">34716119</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giudici</surname><given-names>N.</given-names></name><name><surname>Bonne</surname><given-names>F.</given-names></name><name><surname>Blarer</surname><given-names>J.</given-names></name><name><surname>Minoli</surname><given-names>M.</given-names></name><name><surname>Krentel</surname><given-names>F.</given-names></name><name><surname>Seiler</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review</article-title>. <source>Transl. Androl. Urol.</source>
<volume>10</volume> (<issue>10</issue>), <fpage>4036</fpage>&#x02013;<lpage>4050</lpage>. <pub-id pub-id-type="doi">10.21037/tau-20-1472</pub-id>
<pub-id pub-id-type="pmid">34804846</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>G&#x000fc;nzel</surname><given-names>D.</given-names></name><name><surname>Fromm</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Claudins and other tight junction proteins</article-title>. <source>Compr. Physiol.</source>
<volume>2</volume> (<issue>3</issue>), <fpage>1819</fpage>&#x02013;<lpage>1852</lpage>. <pub-id pub-id-type="doi">10.1002/cphy.c110045</pub-id>
<pub-id pub-id-type="pmid">23723025</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guti&#x000e9;rrez</surname><given-names>F. J. Q.</given-names></name><name><surname>Panizo</surname><given-names>&#x000c1;.</given-names></name><name><surname>Tienza</surname><given-names>A.</given-names></name><name><surname>Rodriguez</surname><given-names>I.</given-names></name><name><surname>Sola</surname><given-names>J. J.</given-names></name><name><surname>Temprana-Salvador</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Cytogenetic and immunohistochemical study of 42 pigmented microcystic chromophobe renal cell carcinoma (PMChRCC)</article-title>. <source>Virchows Arch.</source>
<volume>473</volume> (<issue>2</issue>), <fpage>209</fpage>&#x02013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1007/s00428-018-2389-y</pub-id>
<pub-id pub-id-type="pmid">29931469</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harrison</surname><given-names>M. L.</given-names></name><name><surname>Obermueller</surname><given-names>E.</given-names></name><name><surname>Maisey</surname><given-names>N. R.</given-names></name><name><surname>Hoare</surname><given-names>S.</given-names></name><name><surname>Edmonds</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>N. F.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose</article-title>. <source>J. Clin. Oncol.</source>
<volume>25</volume> (<issue>29</issue>), <fpage>4542</fpage>&#x02013;<lpage>4549</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2007.11.2136</pub-id>
<pub-id pub-id-type="pmid">17925549</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hong</surname><given-names>S. H.</given-names></name><name><surname>Kim</surname><given-names>G.-Y.</given-names></name><name><surname>Chang</surname><given-names>Y.-C.</given-names></name><name><surname>Moon</surname><given-names>S.-K.</given-names></name><name><surname>Kim</surname><given-names>W.-J.</given-names></name><name><surname>Choi</surname><given-names>Y. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Bufalin prevents the migration and invasion of T24 bladder carcinoma cells through the inactivation of matrix metalloproteinases and modulation of tight junctions</article-title>. <source>Int. J. Oncol.</source>
<volume>42</volume> (<issue>1</issue>), <fpage>277</fpage>&#x02013;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2012.1683</pub-id>
<pub-id pub-id-type="pmid">23128598</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Luan</surname><given-names>J.</given-names></name><name><surname>Duan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Yagasaki</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action</article-title>. <source>Cytotechnology</source>
<volume>62</volume> (<issue>6</issue>), <fpage>573</fpage>&#x02013;<lpage>583</lpage>. <pub-id pub-id-type="doi">10.1007/s10616-010-9310-0</pub-id>
<pub-id pub-id-type="pmid">20963488</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jing</surname><given-names>P.</given-names></name><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name></person-group> (<year>2013</year>). <article-title>&#x00394;Np63 promotes UM-UC-3 cell invasiveness and migration through claudin-1 <italic>in vitro</italic>
</article-title>. <source>Mol. Med. Rep.</source>
<volume>7</volume> (<issue>3</issue>), <fpage>1026</fpage>&#x02013;<lpage>1030</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2013.1271</pub-id>
<pub-id pub-id-type="pmid">23313968</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kardos</surname><given-names>J.</given-names></name><name><surname>Chai</surname><given-names>S.</given-names></name><name><surname>Mose</surname><given-names>L. E.</given-names></name><name><surname>Selitsky</surname><given-names>S. R.</given-names></name><name><surname>Krishnan</surname><given-names>B.</given-names></name><name><surname>Saito</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</article-title>. <source>JCI Insight</source>
<volume>1</volume> (<issue>3</issue>), <fpage>e85902</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.85902</pub-id>
<pub-id pub-id-type="pmid">27699256</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. S.</given-names></name><name><surname>Choi</surname><given-names>Y. D.</given-names></name><name><surname>Jin</surname><given-names>X. M.</given-names></name><name><surname>Cho</surname><given-names>Y. M.</given-names></name><name><surname>Jang</surname><given-names>J. J.</given-names></name><name><surname>Juhng</surname><given-names>S. W.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Immunohistochemical stain for cytokeratin 7, S100A1 and claudin 8 is valuable in differential diagnosis of chromophobe renal cell carcinoma from renal oncocytoma</article-title>. <source>Histopathology</source>
<volume>54</volume> (<issue>5</issue>), <fpage>633</fpage>&#x02013;<lpage>635</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2559.2009.03271.x</pub-id>
<pub-id pub-id-type="pmid">19302533</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kind</surname><given-names>S.</given-names></name><name><surname>B&#x000fc;scheck</surname><given-names>F.</given-names></name><name><surname>H&#x000f6;flmayer</surname><given-names>D.</given-names></name><name><surname>Hube-Magg</surname><given-names>C.</given-names></name><name><surname>Kluth</surname><given-names>M.</given-names></name><name><surname>Tsourlakis</surname><given-names>M. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer</article-title>. <source>World J. Urology</source>
<volume>38</volume> (<issue>9</issue>), <fpage>2185</fpage>&#x02013;<lpage>2196</lpage>. <pub-id pub-id-type="doi">10.1007/s00345-019-03017-w</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kojima</surname><given-names>T.</given-names></name><name><surname>Kohno</surname><given-names>T.</given-names></name><name><surname>Kubo</surname><given-names>T.</given-names></name><name><surname>Kaneko</surname><given-names>Y.</given-names></name><name><surname>Kakuki</surname><given-names>T.</given-names></name><name><surname>Kakiuchi</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Regulation of claudin-4 via p63 in human epithelial cells</article-title>. <source>Ann. N. Y. Acad. Sci.</source>
<volume>1405</volume> (<issue>1</issue>), <fpage>25</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.13456</pub-id>
<pub-id pub-id-type="pmid">28856683</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolle</surname><given-names>G.</given-names></name><name><surname>Georgas</surname><given-names>K.</given-names></name><name><surname>Holmes</surname><given-names>G. P.</given-names></name><name><surname>Little</surname><given-names>M. H.</given-names></name><name><surname>Yamada</surname><given-names>T.</given-names></name></person-group> (<year>2000</year>). <article-title>CRIM1, a novel gene encoding a cysteine-rich repeat protein, is developmentally regulated and implicated in vertebrate CNS development and organogenesis</article-title>. <source>Mech. Dev.</source>
<volume>90</volume> (<issue>2</issue>), <fpage>181</fpage>&#x02013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/S0925-4773(99)00248-8</pub-id>
<pub-id pub-id-type="pmid">10642437</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krajewska</surname><given-names>M.</given-names></name><name><surname>Olson</surname><given-names>A. H.</given-names></name><name><surname>Mercola</surname><given-names>D.</given-names></name><name><surname>Reed</surname><given-names>J. C.</given-names></name><name><surname>Krajewski</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate</article-title>. <source>Prostate</source>
<volume>67</volume> (<issue>9</issue>), <fpage>907</fpage>&#x02013;<lpage>910</lpage>. <pub-id pub-id-type="doi">10.1002/pros.20578</pub-id>
<pub-id pub-id-type="pmid">17440968</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>B.</given-names></name><name><surname>Ahmad</surname><given-names>R.</given-names></name><name><surname>Giannico</surname><given-names>G. A.</given-names></name><name><surname>Zent</surname><given-names>R.</given-names></name><name><surname>Talmon</surname><given-names>G. A.</given-names></name><name><surname>Harris</surname><given-names>R. C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation</article-title>. <source>J. Exp. Clin. Cancer Res.</source>
<volume>40</volume> (<issue>1</issue>), <fpage>77</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-021-01870-5</pub-id>
<pub-id pub-id-type="pmid">33622361</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuwada</surname><given-names>M.</given-names></name><name><surname>Chihara</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Nishiguchi</surname><given-names>Y.</given-names></name><name><surname>Fujiwara</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer</article-title>. <source>Cancer Lett.</source>
<volume>369</volume> (<issue>1</issue>), <fpage>212</fpage>&#x02013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2015.08.019</pub-id>
<pub-id pub-id-type="pmid">26342407</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Landers</surname><given-names>K. A.</given-names></name><name><surname>Samaratunga</surname><given-names>H.</given-names></name><name><surname>Teng</surname><given-names>L.</given-names></name><name><surname>Buck</surname><given-names>M.</given-names></name><name><surname>Burger</surname><given-names>M. J.</given-names></name><name><surname>Scells</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer</article-title>. <source>Br. J. Cancer</source>
<volume>99</volume> (<issue>3</issue>), <fpage>491</fpage>&#x02013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6604486</pub-id>
<pub-id pub-id-type="pmid">18648369</pub-id>
</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larkin</surname><given-names>J. M. G.</given-names></name><name><surname>Ferguson</surname><given-names>T. R.</given-names></name><name><surname>Pickering</surname><given-names>L. M.</given-names></name><name><surname>Edmonds</surname><given-names>K.</given-names></name><name><surname>James</surname><given-names>M. G.</given-names></name><name><surname>Thomas</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma</article-title>. <source>Br. J. Cancer</source>
<volume>103</volume> (<issue>8</issue>), <fpage>1149</fpage>&#x02013;<lpage>1153</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6605889</pub-id>
<pub-id pub-id-type="pmid">20842130</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lechpammer</surname><given-names>M.</given-names></name><name><surname>Resnick</surname><given-names>M. B.</given-names></name><name><surname>Sabo</surname><given-names>E.</given-names></name><name><surname>Yakirevich</surname><given-names>E.</given-names></name><name><surname>O Greaves</surname><given-names>W.</given-names></name><name><surname>T Sciandra</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>The diagnostic and prognostic utility of claudin expression in renal cell neoplasms</article-title>. <source>Mod. Pathol.</source>
<volume>21</volume> (<issue>11</issue>), <fpage>1320</fpage>&#x02013;<lpage>1329</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.2008.116</pub-id>
<pub-id pub-id-type="pmid">18587324</pub-id>
</mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Yao</surname><given-names>J. L.</given-names></name><name><surname>di Sant'Agnese</surname><given-names>P. A.</given-names></name><name><surname>Bourne</surname><given-names>P. A.</given-names></name><name><surname>Picken</surname><given-names>M. M.</given-names></name><name><surname>Young</surname><given-names>A. N.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Expression of claudin-7 in benign kidney and kidney tumors</article-title>. <source>Int. J. Clin. Exp. Pathol.</source>
<volume>1</volume> (<issue>1</issue>), <fpage>57</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">18784823</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Gong</surname><given-names>Y.</given-names></name><name><surname>Ning</surname><given-names>X.</given-names></name><name><surname>Peng</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis</article-title>. <source>J. Exp. Clin. Cancer Res.</source>
<volume>37</volume> (<issue>1</issue>), <fpage>276</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-018-0924-y</pub-id>
<pub-id pub-id-type="pmid">30428910</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Medici</surname><given-names>D.</given-names></name><name><surname>Hay</surname><given-names>E. D.</given-names></name><name><surname>Goodenough</surname><given-names>D. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelial-mesenchymal transition</article-title>. <source>Mol. Biol. Cell</source>
<volume>17</volume> (<issue>4</issue>), <fpage>1871</fpage>&#x02013;<lpage>1879</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.e05-08-0767</pub-id>
<pub-id pub-id-type="pmid">16467384</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Men</surname><given-names>W.</given-names></name><name><surname>Martin</surname><given-names>T. A.</given-names></name><name><surname>Ruge</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Du</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Expression of claudins in human clear cell renal cell carcinoma</article-title>. <source>Cancer Genomics Proteomics</source>
<volume>12</volume> (<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25560639</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mikuteit</surname><given-names>M.</given-names></name><name><surname>Zsch&#x000e4;bitz</surname><given-names>S.</given-names></name><name><surname>St&#x000f6;hr</surname><given-names>C.</given-names></name><name><surname>Herrmann</surname><given-names>E.</given-names></name><name><surname>Polifka</surname><given-names>I.</given-names></name><name><surname>Agaimy</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>The prognostic impact of Claudin 6 in papillary renal cell carcinoma</article-title>. <source>Pathology - Res. Pract.</source>
<volume>231</volume>, <fpage>153802</fpage>. <pub-id pub-id-type="doi">10.1016/j.prp.2022.153802</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakanishi</surname><given-names>K.</given-names></name><name><surname>Ogata</surname><given-names>S.</given-names></name><name><surname>Hiroi</surname><given-names>S.</given-names></name><name><surname>Tominaga</surname><given-names>S.</given-names></name><name><surname>Aida</surname><given-names>S.</given-names></name><name><surname>Kawai</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>Expression of occludin and claudins 1, 3, 4, and 7 in urothelial carcinoma of the upper urinary tract</article-title>. <source>Am. J. Clin. Pathology</source>
<volume>130</volume> (<issue>1</issue>), <fpage>43</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1309/u77a6btexvca5d0e</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Necchi</surname><given-names>A.</given-names></name><name><surname>Raggi</surname><given-names>D.</given-names></name><name><surname>Gallina</surname><given-names>A.</given-names></name><name><surname>Ross</surname><given-names>J. S.</given-names></name><name><surname>Far&#x000e8;</surname><given-names>E.</given-names></name><name><surname>Giannatempo</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer</article-title>. <source>Eur. Urol.</source>
<volume>77</volume> (<issue>6</issue>), <fpage>701</fpage>&#x02013;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2020.02.028</pub-id>
<pub-id pub-id-type="pmid">32165065</pub-id>
</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ogasawara</surname><given-names>N.</given-names></name><name><surname>Kudo</surname><given-names>T.</given-names></name><name><surname>Sato</surname><given-names>M.</given-names></name><name><surname>Kawasaki</surname><given-names>Y.</given-names></name><name><surname>Yonezawa</surname><given-names>S.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Reduction of membrane protein CRIM1 decreases E-cadherin and increases claudin-1 and MMPs, enhancing the migration and invasion of renal carcinoma cells</article-title>. <source>Biol. Pharm. Bull.</source>
<volume>41</volume> (<issue>4</issue>), <fpage>604</fpage>&#x02013;<lpage>611</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b17-00990</pub-id>
<pub-id pub-id-type="pmid">29607933</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ohe</surname><given-names>C.</given-names></name><name><surname>Kuroda</surname><given-names>N.</given-names></name><name><surname>Takasu</surname><given-names>K.</given-names></name><name><surname>Senzaki</surname><given-names>H.</given-names></name><name><surname>Shikata</surname><given-names>N.</given-names></name><name><surname>Yamaguchi</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Utility of immunohistochemical analysis of KAI1, epithelial-specific antigen, and epithelial-related antigen for distinction of chromophobe renal cell carcinoma, an eosinophilic variant from renal oncocytoma</article-title>. <source>Med. Mol. Morphol.</source>
<volume>45</volume> (<issue>2</issue>), <fpage>98</fpage>&#x02013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1007/s00795-011-0546-3</pub-id>
<pub-id pub-id-type="pmid">22718295</pub-id>
</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orea</surname><given-names>M. J.</given-names></name><name><surname>Angulo</surname><given-names>J. C.</given-names></name><name><surname>Gonz&#x000e1;lez-Corpas</surname><given-names>A.</given-names></name><name><surname>Echegaray</surname><given-names>D.</given-names></name><name><surname>Marv&#x000e1;</surname><given-names>M.</given-names></name><name><surname>Lobo</surname><given-names>M. V. T.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Claudin-3 loss of expression is a prognostic marker in castration-resistant prostate cancer</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>24</volume> (<issue>1</issue>), <fpage>803</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24010803</pub-id>
<pub-id pub-id-type="pmid">36614243</pub-id>
</mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Osunkoya</surname><given-names>A. O.</given-names></name><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>Lawson</surname><given-names>D.</given-names></name><name><surname>Picken</surname><given-names>M. M.</given-names></name><name><surname>Amin</surname><given-names>M. B.</given-names></name><name><surname>Young</surname><given-names>A. N.</given-names></name></person-group> (<year>2009</year>). <article-title>Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma</article-title>. <source>Hum. Pathol.</source>
<volume>40</volume> (<issue>2</issue>), <fpage>206</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2008.07.002</pub-id>
<pub-id pub-id-type="pmid">18799195</pub-id>
</mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ouban</surname><given-names>A.</given-names></name><name><surname>Arabi</surname><given-names>T. Z.</given-names></name></person-group> (<year>2023</year>). <article-title>Expression of claudins in preneoplastic conditions of the gastrointestinal tract: a review</article-title>. <source>Cancers</source>
<volume>15</volume> (<issue>16</issue>), <fpage>4095</fpage>. <pub-id pub-id-type="doi">10.3390/cancers15164095</pub-id>
<pub-id pub-id-type="pmid">37627123</pub-id>
</mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Owari</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name><name><surname>Fujii</surname><given-names>K.</given-names></name><name><surname>Fujiwara-Tani</surname><given-names>R.</given-names></name><name><surname>Kishi</surname><given-names>S.</given-names></name><name><surname>Mori</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Role of nuclear claudin-4 in renal cell carcinoma</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>21</volume> (<issue>21</issue>), <fpage>8340</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21218340</pub-id>
<pub-id pub-id-type="pmid">33172177</pub-id>
</mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>B.-J.</given-names></name><name><surname>Lee</surname><given-names>S.-J.</given-names></name><name><surname>Kim</surname><given-names>J. I.</given-names></name><name><surname>Lee</surname><given-names>S.-J.</given-names></name><name><surname>Lee</surname><given-names>C.-H.</given-names></name><name><surname>Chang</surname><given-names>S.-G.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Frequent alteration of p63 expression in human primary bladder carcinomas</article-title>. <source>Cancer Res.</source>
<volume>60</volume> (<issue>13</issue>), <fpage>3370</fpage>&#x02013;<lpage>3374</lpage>.<pub-id pub-id-type="pmid">10910040</pub-id>
</mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Radi</surname><given-names>D. A.</given-names></name><name><surname>Abd-Elazeem</surname><given-names>M. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Prognostic significance of lymphatic vessel density detected by D2-40 and its relation to claudin-4 expression in prostatic adenocarcinoma</article-title>. <source>Int. J. Surg. Pathology</source>
<volume>24</volume> (<issue>3</issue>), <fpage>219</fpage>&#x02013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1177/1066896915611488</pub-id>
</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rini</surname><given-names>B. I.</given-names></name><name><surname>Campbell</surname><given-names>S. C.</given-names></name><name><surname>Escudier</surname><given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>Renal cell carcinoma</article-title>. <source>Lancet</source>
<volume>373</volume> (<issue>9669</issue>), <fpage>1119</fpage>&#x02013;<lpage>1132</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(09)60229-4</pub-id>
<pub-id pub-id-type="pmid">19269025</pub-id>
</mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>S&#x00103;ndulescu</surname><given-names>A.</given-names></name><name><surname>Stepan</surname><given-names>A. E.</given-names></name><name><surname>M&#x00103;rg&#x00102;ritescu</surname><given-names>C.</given-names></name><name><surname>Badiu</surname><given-names>A. M.</given-names></name><name><surname>Matei</surname><given-names>M.</given-names></name><name><surname>Simionescu</surname><given-names>C. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Claudin-4 immunoexpression in urothelial carcinomas</article-title>. <source>Curr. Health Sci. J.</source>
<volume>46</volume> (<issue>4</issue>), <fpage>379</fpage>&#x02013;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.12865/chsj.46.04.08</pub-id>
<pub-id pub-id-type="pmid">33717512</pub-id>
</mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>S&#x00103;ndulescu</surname><given-names>A. &#x0015e;.</given-names></name><name><surname>Stepan</surname><given-names>A. E.</given-names></name><name><surname>M&#x00103;rg&#x00103;ritescu</surname><given-names>C.</given-names></name><name><surname>En&#x00103;chescu</surname><given-names>V.</given-names></name><name><surname>Mitroi</surname><given-names>G.</given-names></name><name><surname>Simionescu</surname><given-names>C. E.</given-names></name></person-group> (<year>2022</year>). <article-title>The role of cell adhesion molecules in the progression of bladder urothelial carcinomas</article-title>. <source>Romanian J. Morphol. Embryology</source>
<volume>63</volume> (<issue>1</issue>), <fpage>145</fpage>&#x02013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.47162/rjme.63.1.15</pub-id>
</mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seo</surname><given-names>K. W.</given-names></name><name><surname>Kwon</surname><given-names>Y. K.</given-names></name><name><surname>Kim</surname><given-names>B. H.</given-names></name><name><surname>Kim</surname><given-names>C. I.</given-names></name><name><surname>Chang</surname><given-names>H. S.</given-names></name><name><surname>Choe</surname><given-names>M. S.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Correlation between claudins expression and prognostic factors in prostate cancer</article-title>. <source>Korean J. Urol.</source>
<volume>51</volume> (<issue>4</issue>), <fpage>239</fpage>&#x02013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.4111/kju.2010.51.4.239</pub-id>
<pub-id pub-id-type="pmid">20428425</pub-id>
</mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>G. M.</given-names></name><name><surname>Kallakury</surname><given-names>B. V. S.</given-names></name><name><surname>Sheehan</surname><given-names>C. E.</given-names></name><name><surname>Fisher</surname><given-names>H. A. G.</given-names></name><name><surname>Kaufman</surname><given-names>R. P.</given-names></name><name><surname>Ross</surname><given-names>J. S.</given-names></name></person-group> (<year>2007</year>). <article-title>Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas</article-title>. <source>Hum. Pathol.</source>
<volume>38</volume> (<issue>4</issue>), <fpage>564</fpage>&#x02013;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2006.11.007</pub-id>
<pub-id pub-id-type="pmid">17306334</pub-id>
</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shin</surname><given-names>D.</given-names></name><name><surname>Cha</surname><given-names>H.-J.</given-names></name><name><surname>Kim</surname><given-names>G.-Y.</given-names></name><name><surname>Kim</surname><given-names>W.-J.</given-names></name><name><surname>Choi</surname><given-names>Y.</given-names></name></person-group> (<year>2013</year>). <article-title>Inhibiting invasion into human bladder carcinoma 5637 cells with diallyl trisulfide by inhibiting matrix metalloproteinase activities and tightening tight junctions</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>14</volume> (<issue>10</issue>), <fpage>19911</fpage>&#x02013;<lpage>19922</lpage>. <pub-id pub-id-type="doi">10.3390/ijms141019911</pub-id>
<pub-id pub-id-type="pmid">24084732</pub-id>
</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shin</surname><given-names>H. I.</given-names></name><name><surname>Kim</surname><given-names>B. H.</given-names></name><name><surname>Chang</surname><given-names>H. S.</given-names></name><name><surname>Kim</surname><given-names>C. I.</given-names></name><name><surname>Jung</surname><given-names>H. R.</given-names></name><name><surname>Park</surname><given-names>C. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Expression of claudin-1 and -7 in clear cell renal cell carcinoma and its clinical significance</article-title>. <source>Korean J. Urology</source>
<volume>52</volume> (<issue>5</issue>), <fpage>317</fpage>&#x02013;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.4111/kju.2011.52.5.317</pub-id>
</mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>N. P.</given-names></name><name><surname>Vinod</surname><given-names>P. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma</article-title>. <source>Mol. Genet. Genomics</source>
<volume>295</volume> (<issue>3</issue>), <fpage>807</fpage>&#x02013;<lpage>824</lpage>. <pub-id pub-id-type="doi">10.1007/s00438-020-01664-y</pub-id>
<pub-id pub-id-type="pmid">32185457</pub-id>
</mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singhal</surname><given-names>S.</given-names></name><name><surname>Marwell</surname><given-names>J. G.</given-names></name><name><surname>Khaki</surname><given-names>A. R.</given-names></name></person-group> (<year>2023</year>). <article-title>Geriatric assessment in the older adult with genitourinary cancer: a narrative review</article-title>. <source>Front. Oncol.</source>
<volume>13</volume>, <fpage>1124309</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2023.1124309</pub-id>
<pub-id pub-id-type="pmid">36816955</pub-id>
</mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>N.</given-names></name><name><surname>Saunders</surname><given-names>D.</given-names></name><name><surname>Lerner</surname><given-names>M.</given-names></name><name><surname>Zalles</surname><given-names>M.</given-names></name><name><surname>Mamedova</surname><given-names>N.</given-names></name><name><surname>Cheong</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>
<italic>In vivo</italic> and <italic>ex vivo</italic> assessment of bladder hyper-permeability and using molecular targeted magnetic resonance imaging to detect claudin-2 in a mouse model for interstitial cystitis</article-title>. <source>PLOS ONE</source>
<volume>15</volume> (<issue>10</issue>), <fpage>e0239282</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0239282</pub-id>
<pub-id pub-id-type="pmid">33095778</pub-id>
</mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soini</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Claudins in lung diseases</article-title>. <source>Respir. Res.</source>
<volume>12</volume> (<issue>1</issue>), <fpage>70</fpage>. <pub-id pub-id-type="doi">10.1186/1465-9921-12-70</pub-id>
<pub-id pub-id-type="pmid">21619599</pub-id>
</mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sz&#x000e1;sz</surname><given-names>A. M.</given-names></name><name><surname>Nyir&#x000e1;dy</surname><given-names>P.</given-names></name><name><surname>Majoros</surname><given-names>A.</given-names></name><name><surname>Szendr&#x000f5;i</surname><given-names>A.</given-names></name><name><surname>Sz&#x000fb;cs</surname><given-names>M.</given-names></name><name><surname>Sz&#x000e9;kely</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression</article-title>. <source>BJU Int.</source>
<volume>105</volume> (<issue>5</issue>), <fpage>716</fpage>&#x02013;<lpage>722</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2009.08808.x</pub-id>
<pub-id pub-id-type="pmid">19818082</pub-id>
</mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sz&#x000e9;kely</surname><given-names>E.</given-names></name><name><surname>T&#x000f6;rzs&#x000f6;k</surname><given-names>P.</given-names></name><name><surname>Riesz</surname><given-names>P.</given-names></name><name><surname>Korompay</surname><given-names>A.</given-names></name><name><surname>Fintha</surname><given-names>A.</given-names></name><name><surname>Sz&#x000e9;kely</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder</article-title>. <source>J. Histochem. Cytochem.</source>
<volume>59</volume> (<issue>10</issue>), <fpage>932</fpage>&#x02013;<lpage>941</lpage>. <pub-id pub-id-type="doi">10.1369/0022155411418829</pub-id>
<pub-id pub-id-type="pmid">21832144</pub-id>
</mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takai</surname><given-names>N.</given-names></name><name><surname>Kira</surname><given-names>N.</given-names></name><name><surname>Ishii</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Nishida</surname><given-names>M.</given-names></name><name><surname>Nishida</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Bufalin, a traditional oriental medicine, induces apoptosis in human cancer cells</article-title>. <source>Asian Pac J. Cancer Prev.</source>
<volume>13</volume> (<issue>1</issue>), <fpage>399</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.7314/apjcp.2012.13.1.399</pub-id>
<pub-id pub-id-type="pmid">22502710</pub-id>
</mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>T&#x000f6;rzs&#x000f6;k</surname><given-names>P.</given-names></name><name><surname>Riesz</surname><given-names>P.</given-names></name><name><surname>Kenessey</surname><given-names>I.</given-names></name><name><surname>Sz&#x000e9;kely</surname><given-names>E.</given-names></name><name><surname>Somor&#x000e1;cz</surname><given-names>&#x000c1;.</given-names></name><name><surname>Nyir&#x000e1;dy</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Claudins and ki-67: potential markers to differentiate low- and high-grade transitional cell carcinomas of the urinary bladder</article-title>. <source>J. Histochem. Cytochem.</source>
<volume>59</volume> (<issue>11</issue>), <fpage>1022</fpage>&#x02013;<lpage>1030</lpage>. <pub-id pub-id-type="doi">10.1369/0022155411424606</pub-id>
<pub-id pub-id-type="pmid">22043024</pub-id>
</mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Truong</surname><given-names>L. D.</given-names></name><name><surname>Shen</surname><given-names>S. S.</given-names></name></person-group> (<year>2011</year>). <article-title>Immunohistochemical diagnosis of renal neoplasms</article-title>. <source>Archives Pathology Laboratory Med.</source>
<volume>135</volume> (<issue>1</issue>), <fpage>92</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1043/2010-0478-RAR.1</pub-id>
</mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsukita</surname><given-names>S.</given-names></name><name><surname>Tanaka</surname><given-names>H.</given-names></name><name><surname>Tamura</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>The claudins: from tight junctions to biological systems</article-title>. <source>Trends Biochem. Sci.</source>
<volume>44</volume> (<issue>2</issue>), <fpage>141</fpage>&#x02013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2018.09.008</pub-id>
<pub-id pub-id-type="pmid">30665499</pub-id>
</mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>V&#x000e4;re</surname><given-names>P.</given-names></name><name><surname>Loikkanen</surname><given-names>I.</given-names></name><name><surname>Hirvikoski</surname><given-names>P.</given-names></name><name><surname>Vaarala</surname><given-names>M. H.</given-names></name><name><surname>Soini</surname><given-names>Y.</given-names></name></person-group> (<year>2008</year>). <article-title>Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma</article-title>. <source>Oncol. Rep.</source>
<volume>19</volume> (<issue>1</issue>), <fpage>25</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.3892/or.19.1.25</pub-id>
<pub-id pub-id-type="pmid">18097572</pub-id>
</mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venugopal</surname><given-names>S.</given-names></name><name><surname>Anwer</surname><given-names>S.</given-names></name><name><surname>Sz&#x000e1;szi</surname><given-names>K.</given-names></name></person-group> (<year>2019</year>). <article-title>Claudin-2: roles beyond permeability functions</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>20</volume> (<issue>22</issue>), <fpage>5655</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20225655</pub-id>
<pub-id pub-id-type="pmid">31726679</pub-id>
</mixed-citation></ref><ref id="B74"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>R. S.</given-names></name><name><surname>Merk</surname><given-names>F. B.</given-names></name><name><surname>Alroy</surname><given-names>J.</given-names></name></person-group> (<year>1976</year>). &#x0201c;<article-title>The structure and function of intercellular junctions in cancer</article-title>,&#x0201d; in <source>Advances in cancer research</source>. Editors <person-group person-group-type="editor"><name><surname>Kleln</surname><given-names>G.</given-names></name><name><surname>Weinhouse</surname><given-names>S.</given-names></name><name><surname>Haddow</surname><given-names>A.</given-names></name></person-group> (<publisher-loc>Cambridge</publisher-loc>: <publisher-name>Academic Press</publisher-name>), <fpage>23</fpage>&#x02013;<lpage>89</lpage>.</mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Worst</surname><given-names>T. S.</given-names></name><name><surname>Von Hardenberg</surname><given-names>J.</given-names></name><name><surname>Gross</surname><given-names>J. C.</given-names></name><name><surname>Erben</surname><given-names>P.</given-names></name><name><surname>Schn&#x000f6;lzer</surname><given-names>M.</given-names></name><name><surname>Hausser</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Database-augmented mass spectrometry analysis of exosomes identifies claudin 3 as a putative prostate cancer biomarker</article-title>. <source>Mol. Cell. Proteomics</source>
<volume>16</volume> (<issue>6</issue>), <fpage>998</fpage>&#x02013;<lpage>1008</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.m117.068577</pub-id>
<pub-id pub-id-type="pmid">28396511</pub-id>
</mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yadav</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>Y.</given-names></name><name><surname>Dahiya</surname><given-names>D.</given-names></name><name><surname>Bhatia</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Claudins: the newly emerging targets in breast cancer</article-title>. <source>Clin. Breast Cancer</source>
<volume>22</volume> (<issue>8</issue>), <fpage>737</fpage>&#x02013;<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1016/j.clbc.2022.09.001</pub-id>
<pub-id pub-id-type="pmid">36175290</pub-id>
</mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamu&#x000e7;</surname><given-names>E.</given-names></name><name><surname>Bar&#x00131;&#x0015f;&#x00131;k</surname><given-names>N.</given-names></name><name><surname>&#x0015e;ensu</surname><given-names>S.</given-names></name><name><surname>Tarhan</surname><given-names>F.</given-names></name><name><surname>Bar&#x00131;&#x0015f;&#x00131;k</surname><given-names>C. C.</given-names></name></person-group> (<year>2022</year>). <article-title>Correlation of REG1A, Claudin 7 and Ki67 expressions with tumor recurrence and prognostic factors in superficial urothelial urinary bladder carcinomas</article-title>. <source>Indian J. Pathol. Microbiol.</source>
<volume>65</volume> (<issue>2</issue>), <fpage>355</fpage>&#x02013;<lpage>361</lpage>. <pub-id pub-id-type="doi">10.4103/ijpm.Ijpm_914_20</pub-id>
<pub-id pub-id-type="pmid">35435371</pub-id>
</mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Mani</surname><given-names>S. A.</given-names></name><name><surname>Weinberg</surname><given-names>R. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Exploring a new twist on tumor metastasis</article-title>. <source>Cancer Res.</source>
<volume>66</volume> (<issue>9</issue>), <fpage>4549</fpage>&#x02013;<lpage>4552</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-05-3850</pub-id>
<pub-id pub-id-type="pmid">16651402</pub-id>
</mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Ma</surname><given-names>K.</given-names></name><name><surname>Gong</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>CLDN10 associated with immune infiltration is a novel prognostic biomarker for clear cell renal cell carcinoma</article-title>. <source>Epigenomics</source>
<volume>13</volume> (<issue>1</issue>), <fpage>31</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.2217/epi-2020-0256</pub-id>
<pub-id pub-id-type="pmid">33203244</pub-id>
</mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Claudin-10 overexpression suppresses human clear cell renal cell carcinoma growth and metastasis by regulating ATP5O and causing mitochondrial dysfunction</article-title>. <source>Int. J. Biol. Sci.</source>
<volume>18</volume> (<issue>6</issue>), <fpage>2329</fpage>&#x02013;<lpage>2344</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.70105</pub-id>
<pub-id pub-id-type="pmid">35414767</pub-id>
</mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Kang</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Expression and significance of PTEN and Claudin-3 in prostate cancer</article-title>. <source>Oncol. Lett.</source>
<volume>17</volume>, <fpage>5628</fpage>&#x02013;<lpage>5634</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2019.10212</pub-id>
<pub-id pub-id-type="pmid">31186785</pub-id>
</mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J. Y.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Foroohar</surname><given-names>M.</given-names></name><name><surname>Ko</surname><given-names>E.</given-names></name><name><surname>Chan</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Regulation of the expression of the prostate-specific antigen by claudin-7</article-title>. <source>J. Membr. Biol.</source>
<volume>194</volume> (<issue>3</issue>), <fpage>187</fpage>&#x02013;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1007/s00232-003-2038-4</pub-id>
<pub-id pub-id-type="pmid">14502431</pub-id>
</mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title>Combined immunohistochemistry for the &#x0201c;three 7&#x0201d; markers (CK7, CD117, and claudin-7) is useful in the diagnosis of chromophobe renal cell carcinoma and for the exclusion of mimics: diagnostic experience from a single institution</article-title>. <source>Dis. Markers</source>
<volume>2019</volume>, <fpage>4708154</fpage>. <pub-id pub-id-type="doi">10.1155/2019/4708154</pub-id>
<pub-id pub-id-type="pmid">31737127</pub-id>
</mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Claudin family participates in the pathogenesis of inflammatory bowel diseases and colitis-associated colorectal cancer</article-title>. <source>Front. Immunol.</source>
<volume>10</volume>, <fpage>1441</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.01441</pub-id>
<pub-id pub-id-type="pmid">31316506</pub-id>
</mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Lv</surname><given-names>T.</given-names></name><name><surname>Cai</surname><given-names>T.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Prognostic value and potential biological functions of CLDN8 in patients with clear cell renal cell carcinoma</article-title>. <source>Onco Targets Ther.</source>
<volume>13</volume>, <fpage>9135</fpage>&#x02013;<lpage>9145</lpage>. <pub-id pub-id-type="doi">10.2147/ott.S266846</pub-id>
<pub-id pub-id-type="pmid">32982302</pub-id>
</mixed-citation></ref></ref-list></back></article>